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1 Introduction 
1.1 Asthma Immunology 
1.1.1 Epidemiology 
Most recent studies estimate a number of 334 million people worldwide 
suffering from asthma [1]. The World Health Organization (WHO) forecasts that 
the number of asthma patients will even increase by more than 100 million by 
2025 [2]. After decades of regarding asthma as a disease of Western or high-
income countries, this historical view is no longer kept up. In fact, today most 
people with asthma are affected in low- and middle-income countries [1]. 
Whereas the prevalence of asthma is still increasing in these low- and middle-
income countries, it might now be plateauing in some high-income countries [3, 
4]. 
Although asthma is not a deadly disease, it can become very dangerous and 
even life-threatening if not treated and managed properly. According to the 
WHO 250,000 deaths are annually attributed to asthma [2]. Though fatal 
asthma is relatively rare among children, the disease represents a substantial 
burden especially to these young patients. In fact, asthma is the most common 
chronic disease in childhood. In Germany an estimated 10% of all children and 
14% of all children worldwide suffer from asthma [5]. The illness often restricts 
their daily activities and interferes with family life. Reports published by the 
American Lung Association emphasize that asthma is one of the leading causes 
of hospitalization and emergency department visits among children and 
furthermore one of the most important reasons for missed school days [6]. 
Considering the impact and consequences of asthma it does not surprise that 
the disease is ranked 14th in the most important disorders of the world in terms 
of extent and duration of disability [1]. 
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1.1.2 Classification of atopic and non-atopic asthma 
1.1.2.1 Atopy 
The term “atopy” describes the genetic predisposition to develop 
immunoglobulin (Ig) E antibodies against low doses of common environmental 
allergens (e.g. pollen, dander or food) [7]. IgE mediated allergic reactions trigger 
an exaggerated histamine release, causing the symptoms of the classical atopic 
disorders as allergic rhinitis, atopic dermatitis and allergic asthma. The 
classification of “extrinsic” (or atopic) and “intrinsic” (non-atopic) asthma was 
first introduced by Rackemann in 1947 [8]. He emphasized the triggering role of 
allergens in extrinsic asthma and in contrast considered intrinsic asthma to be a 
disease of non-allergic, unknown origin. The present study addresses the 
pathogenic principles of childhood atopic asthma. 
1.1.2.2 Atopic asthma 
Atopic (or extrinsic, allergic) asthma is characterized by an atopic, hence IgE 
mediated, pathogenesis of airway inflammation with an imbalance in T cell 
differentiation towards an exaggerated T helper cell type (Th) 2 immunity to 
allergens in the bronchial mucosa. Besides increased levels of total and 
allergen-specific serum IgE, a positive skin prick test to common allergens 
serves as a diagnostic test. Allergic asthma usually develops in childhood and is 
often accompanied by hay fever and seasonal exacerbations [9]. 
1.1.2.3 Non-atopic asthma 
Most asthma patients are atopic, but a subgroup also suffers from non-atopic 
(or intrinsic) asthma, comprising 
- asthma due to respiratory infections 
- asthma through chemical or toxic irritants 
- exercise-induced asthma 
- analgesic-induced asthma and 
- asthma complaints as a consequence of gastroesophageal reflux [10]. 
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Here, as sensitization is absent, IgE plays a less important role in the 
pathogenesis of the disease [11] and symptoms are not associated with allergic 
reactions. Further immunological mechanisms are less characterized, 
particularly in children. Female predominance, a higher degree of severity, more 
frequent association to nasosinusal polyposis and a later onset in lifetime is 
observed in non-atopic asthma when compared to the atopic form of the 
disease [8, 9]. 
1.1.3 Clinical picture and etiology 
Asthma is a chronic immune-inflammatory disease of the respiratory system. 
Main characteristics are reversible airway obstruction and airway 
hyperresponsiveness (AHR). Although asthma can develop at any stage of life, 
it most commonly develops in early childhood [1]. The character of symptoms 
and the severity of the disease may vary from patient to patient and can range 
from mild, occasional symptoms to severe, persistent complaints. Symptom-free 
periods often alternate with acute exacerbations. Common clinical features 
include wheezing, shortness of breath, chronic coughing, chest tightness or 
pain and increasing production of mucus in the airways (Fig. 1) [12]. 
 
Fig. 1 Normal airway in comparison to an asthmatic bronchiole 
Enlarged smooth muscles, bronchial spasm and excessive mucus secretion lead to an increase 
in breathing difficulty.  
(Adapted and modified from http://www.nlm.nih.gov/medlineplus/ency/imagepages/19346.htm) 
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1.1.3.1 Pathogenesis and etiology 
It is yet unclear what initiates the inflammatory process in asthma disease in the 
first place and which immunological mechanisms make some persons more 
susceptible to asthma than others. Nonetheless, during the past decades much 
has been learned about factors contributing to the development of asthma. Host 
factors, such as genetic predisposition seem to play an important role, as well 
as prenatal factors and environmental exposure. The influence of viral 
respiratory tract infections is controversially discussed [13-18]. However, the 
precise interactions of complex host, environmental and further site-specific 
factors are still subjects of active investigations. 
Host factors 
It is well recognized that asthma has strong inheritable components accounting 
for its pathogenesis. Children of atopic parents are more likely to develop atopy 
or asthma than children of parents not affected by atopy. In fact, if both parents 
have a history of asthma, the offspring’s risk is estimated 60-80% to fall ill [10, 
19]. Notably, maternal asthma increases the children’s risk to develop the 
disease to a greater extent than paternal asthma [20, 21]. 
The development of asthma is dependent on multiple genetic variants and the 
environment. The genetics involved and their interaction are complex and still 
not fully understood [22, 23]. Some research efforts were able to identify genes 
or gene variants that may contribute to or even protect from the development of 
asthma. The gene ORMDL3, encoding transmembrane proteins in the 
endoplasmatic reticulum, has been identified as a susceptibility gene for 
childhood asthma in a genome-wide association study (GWAS) [24, 25]. Since 
its neighboring gene GSDML is co-regulated with ORMDL3 [24, 26], making it 
difficult to clearly distinguish the effects of these two genes, it has been 
suggested to refer to the term “17q21 asthma locus”. Several investigations 
were able to confirm this association [27-29]. Besides the 17q21 locus, meta-
analysis of asthma GWAS suggest three more gene loci to be considered 
asthma susceptibility genes: IL1RL1/IL18R1, TSLP and IL33 [30-32]. Asthma-
associated genetic variants were also found in and close to TLR1, TLR6 and 
TLR10 [33, 34]. Furthermore, mutant alleles in the filaggrin gene were primarily 
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found to be associated with atopic dermatitis [35] and asthma, but only with 
concomitant atopic dermatitis [36, 37]. Interleukin-13 (IL-13) is a mediator of 
allergy produced by Th2 cells and several reports indicate that polymorphisms 
in the IL-13 gene are associated with asthma and/or atopy [38-40]. 
More than 100 candidate genes are currently discussed, but most of them 
require further analysis and systematic studies to determine whether they really 
can be considered as susceptibility genes. 
Sex and sex hormones might also contribute to the pathogenesis of asthma, but 
their relation remains still to be determined. Among school children and at 
puberty the prevalence of asthma is higher in girls, whereas early in life the 
disease is recognized to occur predominantly in boys [41]. 
Environmental factors 
Depending on the agent, environmental influence on the maturing immune and 
organ system of children can both be protective or harmful.  
The noxious effect of tobacco smoke, especially in early childhood, could be 
demonstrated by numerous studies and represents a crucial risk factor for the 
onset of many diseases, including wheezing and asthma [42-44]. Environmental 
tobacco smoke not only increases the prevalence of asthma but also the 
severity of the disease [45]. Furthermore, active smoking is associated with 
asthma in adults and adolescents [46, 47]. Also industrial and traffic air pollution 
during infancy contributes to the development of childhood asthma [48, 49]. 
Protective effects however, seem to emanate from the exposure to antigens or 
microbial products, childhood infections and bacterial endotoxin – in short, 
agents that are considered “unhygienic” in today’s industrialized lifestyle. While 
rising standards of household cleanliness, semi sterile diets, improving health 
care and declining family size are part of today’s Western lifestyle, this trend 
leads to reduced contact to antigens and microbes in early childhood. 
Simultaneously, the prevalence of asthma increased constantly during the past 
decades in developed industrialized countries [50, 51]. With rising standards of 
living and improved hygienic conditions, the prevalence of this disease also 
seems to increase in developing countries [50, 52]. The contributing factors and 
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underlying immunological mechanisms of this observation shall be argued in the 
next chapter (1.1.3.2). 
1.1.3.2 The hygiene hypothesis  
Microbes and other environmental antigens contribute materially to the onset of 
asthma in childhood. In fact, less exposure to these pathogens in early 
childhood is linked to a rise of atopy and allergic diseases during the past 
decades. This observation is referred to as the hygiene hypothesis and was first 
introduced by D. Strachan in 1989. In his study, Strachan followed a large 
sample of British children from birth until the age of 23 and was able to show 
that their risk to develop hay fever was inversely related to the number of 
children in the household [13]. He reasoned that infections in early childhood, 
possibly transmitted by older siblings, might have a preventive effect on later 
allergic diseases. Empirical findings of several studies supported this 
observation and confirmed that a higher number of siblings might have 
protective effect not only against hay fever but also against allergic eczema and 
asthma [14, 53, 54]. 
The role of recurrent infections in the development of childhood asthma is still 
not definitely determined. There is widespread evidence that certain infections, 
including measles, and exposure to infectious agents early in life protect against 
asthma [15-17]. Severe infections with respiratory syncytial virus in early 
childhood, however, are associated with an increased risk for the onset of 
asthma and allergic sensitization [14, 18]. 
Growing up in the environment of traditional farms, where exposure to a large 
range of microbes is typical, was also found to protect from childhood asthma 
and atopy [55-57], supporting the principles of the hygiene hypothesis. 
However, the term “farming” can cover a variety of dissimilar surroundings and 
one farm is not just like another: Children exposed to highly modernized 
concentrated animal feeding operations, mostly common in the USA, have an 
increased risk to develop asthma (but not atopy or allergies in general) [58, 59]. 
In fact, a greater diversity of microbial agents afforded on farms is associated 
with the protection from asthma [60]. 
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Soon, immunological mechanisms were sought to explain and combine the 
findings of the hygiene hypothesis with the development of atopic asthma. In 
this regard, the maturation process of T helper cell responses in early life was 
found to play a major role. In the immune system, T cells are, beside B cells, 
one of the main types of lymphocytes and hold a key part in cell-mediated 
immunity. Another type are natural killer (NK) cells which have the same 
progenitors as T and B cells and are able to kill malignant or virus infected cells 
by secreting cytotoxic granules. T cells originate from the bone marrow but have 
to migrate to the thymus where naïve CD4+ T cells differentiate into different 
T lymphocyte subsets such as Th1, Th2, Th17 or regulatory T cells (Tregs). The 
direction of the complex maturation process takes place according to the tissue 
cytokine context. It furthermore depends on the activation of specific translation 
factors and is influenced by surrounding partner cells secreting certain 
cytokines. The various subgroups of CD4+ T cells show distinct cytokine 
expression profiles and carry out very different functions. Cytokines occupy a 
central position as they are both produced by the T lymphocytes to mediate 
many of their specific functions and also in turn influence the polarization and 
maturation of these T cell subsets. In brief, Th1 cells mainly produce IL-2 and 
IFNγ and play a pivotal role in cell-mediated immunity by stimulating 
phagocytosis. A Th1 predominated immune profile is associated with 
autoimmune diseases. Th2 cells initiate the humoral immunity via B cell 
activation and can promote allergic responses. In order to mediate allergic 
reactions these cells secrete IL-4, -5, -6, -9, -10 and -13. Accordingly, a 
predominant Th2 profile is associated with allergic asthma. Th17 cells secrete 
IL-17 and IL-22, play a crucial role in acute inflammation and are implicated in 
autoimmune reactions. Tregs however, are responsible to suppress T cell 
activity (once the pathogen has been eliminated) rather than inducing it. 
Thereby they maintain immunotolerance and prevent autoimmunity. Tregs 
produce TGF-β and IL-10. Of course a well-functioning immune system implies 




In the newborn period the innate immune system begins to shift from a fetal 
Th2-dominated phenotype towards an adult, more balanced immune profile with 
increased Th1 reactivity [61, 62]. During this vulnerable time frame and already 
during pregnancy, various stimuli such as exposure to microbes, pathogens and 
viral infections are pivotal to induce this gradual maturation of the Th1 response 
[63, 64]. 
Absence of exposure to these agents is subsequently associated with a delay of 
T cell maturation and a tendency for the predominant Th2 profile to persist. This 
imbalance in favor of Th2 cells has been shown to play a determining role in the 
onset of atopy and allergic inflammation later in life. 
Investigations in mouse models showed that cell transfer and overexpression of 
Th2 cytokines in murine airway epithelial cells lead to asthma symptoms such 
as increased secretion of mucus, AHR and eosinophilia [65, 66]. In fact, Th2 but 
not Th1 cells could be directly linked to the onset of AHR [67]. In humans, 
Th2 lymphocytes and Th2-like cytokines, mainly IL-4 and -5, were found to be 
increased in the bronchial mucosa of asthma patients and contribute to the 
development of the disease [68, 69]. Elevated levels of allergen induced IL-4 
and IL-9 were detected in children with atopic asthma [70]. A primarily Th2-
orientated immune system lays groundwork for the production of IgE antibodies 
to environmental antigens and subsequent development of atopic sensitization. 
The mechanism is initiated by Th2 cells secreting IL-4, thereby inducing an 
isotype switch and IgE production in B cells. T cell cytokines IL-13 and IL-9 
further enhance IgE synthesis [71-73]. Th1 cells however are able to 
downregulate IgE synthesis by producing IFNγ. As mentioned previously, Tregs 
function as opponents as they secrete IL-10 to inhibit both Th1 and Th2 cell 
signaling and IgE production [72, 74]. As IgE activates its receptor, e.g. on mast 
cells, a wide range of mediators are released which promote the secretion of 
pro-inflammatory cytokines and initiate typical asthma symptoms such as 
bronchial spasm [75-77]. 
In summary, the hygiene hypothesis postulates that exposure to an 
environment rich in microbes in early childhood influences the maturation of the 
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immune system, promoting a “non-allergic” pathway, resulting in a decreased 
risk of asthma and other allergic diseases. An imbalance in T cell responses 
with a predominant Th2 profile is associated with the onset of asthma. However, 
many aspects of this theory are still fiercely debated. Although there is 
widespread evidence for this hypothesis being a crucial underlying cause for the 
rising of atopy in developed countries, the hygiene hypothesis should not be 
regarded as the sole explanation for the increasing and constantly high 
prevalence of asthma. 
1.1.3.3 Pathophysiology 
The interaction of genetic predisposition and further predisposing factors in the 
first years of life, eventually leading to the development of airway inflammation 
and asthma, is heterogeneous and still not fully understood. It is, however, 
generally agreed that inflammation plays a central role in the pathogenesis and 
pathophysiology of asthma. Trigger factors (Table 1 in chapter 1.1.3.4) are 
relevant when encountering hyperresponsive airways, initiating complex 
immunological and physiological mechanisms [78]. In brief, inhaled antigens 
activate mast cells in the airway. The activated cells secrete mediators such as 
histamine and leukotrienes, inducing not only bronchoconstriction but also 
promoting inflammation [79, 80]. Antigens further activate Th2 cells, which 
thereupon release cytokines such as IL-4, -5 and -13. As already described, 
some Th2 cytokines initiate IgE synthesis in B cells. IL-5 induces differentiation 
of eosinophils in the bone marrow. Eosinophils then enter the inflamed airway, 
release yet more pro-inflammatory cytokines and are kept alive by IL-4 contact. 
In addition, macrophages, smooth muscle cells, fibroblasts and also airway 
epithelial cells produce inflammatory mediators that amplify the inflammatory 
response [78, 81]. 
As in every inflammatory reaction, increased blood flow occurs, causing edema 
and swelling of the mucosa. Smooth muscle cells surrounding the bronchioles 
tighten and goblet epithelial cells produce more viscous thick mucus. Some 
patients can develop persistent changes in airway structure in later years, 
referred to as airway remodeling. These permanent alterations may include 
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smooth muscle hyperthrophy, thickening of the sub-basement membrane, sub-
epithelial fibrosis and angiogenesis [78]. 
All these mechanisms cause airflow limitation by reducing the diameter of the 
airway where even a small decrease has a huge impact on airflow resistance 
and causes difficulty of breathing. Mainly expiration of breath is becoming 
difficult for asthma patients and the typical “wheezing” occurs. The less air the 
patient is able to breathe out, the less fresh air and oxygen he is able to inhale. 
This increasing breathlessness can lead to fear of asphyxiation, resulting in 
increasing stress, panic and even more severe airway obstruction. To early stop 
or preferentially to prevent this vicious circle, asthma needs to be treated and 
managed carefully. 
Asthma medications include short- and long-term controller medications as well 
as rescue drugs. Inhaled corticosteroids dampen inflammation, are anti-allergic 
and immunosuppressive and therefore represent the foundation to provide good 
asthma control. In order to counteract the worsening of bronchial spasm, 
bronchodilators stimulate β2-receptors (therefore also referred to as β2-
agonists) who are responsible for relaxing the tightened smooth muscles 
around the airways. Short-acting β2-agonists are taken as needed, quickly 
relieve or prevent asthma complaints and serve as rescue inhalers. Long-acting 
β2-agonists can be used in combination with inhaled corticosteroids in 
advanced stages of the disease to control chronic symptoms and prevent 
asthma attacks [10]. Leukotriene modifiers can serve as an alternative for some 
patients. These receptor antagonists block pro-inflammatory leukotrienes and 
prevent asthma symptoms [82]. Further alternative medications for moderate to 
severe persistent asthma are theophylline (anti-inflammatory, bronchodilatory) 
and omalizumab (a monoclonal IgE-antibody) [10]. 
Various therapeutic options are available to treat asthma, but most drugs have 
significant side effects or are not suitable for younger children. Although the 
knowledge about pathological mechanisms of the disease as well as research 
and development of new asthma drugs improved rapidly during the last years, 
severe or therapy-resistant asthma is still a major burden. In fact, some studies 
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estimate 5% of all asthma patients to suffer from difficult or drug-resistant 
asthma and new, targeted treatment approaches are necessary to mediacte 
these patients [83]. 
1.1.3.4 Trigger factors 
Asthma exacerbations are caused by excessive reaction of the airways to 
various stimuli. Table 1 states common allergic triggers, leading to airway 
inflammation and smooth muscle contraction, and non-allergic triggers. These 
non-allergic triggers usually don’t initiate inflammation but provoke irritable 
airways. Furthermore some drugs can trigger or induce asthma, such as 
NSAIDs (e.g. aspirin) or β-blockers [10]. Recurrent viral infections are the most 
common initial triggers in infants and toddlers [84, 85]. 
Table 1 Allergic and non-allergic factors that may trigger or worsen asthma 
symptoms 
Allergic triggers Non-allergic triggers 
Pollen Viral infections 
House dust mite Cold, dry air 
Animal dander  Tobacco smoke 
Molds Exercise 
Cockroach Stress 
Insect allergens  
 
1.2 The Toll-like receptor family 
Toll-like receptors (TLRs) owe their name to the famous Drosophila receptor 
protein Toll, discovered by C. Nüsslein-Volhard in the early 1980s [86]. First 
identified to play a crucial role in the embryonic development of Drosophila 
melanogaster, years later Toll was furthermore found to be involved in several 
host-defense mechanisms. Soon, homologs of Toll, subsequently referred to as 
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Toll-like receptors, were also detected in mammalians. In 1997 the first human 
Toll protein and its capability to activate transcription factor NFκB was described 
by R. Medzhitov et al. [87]. Investigations in the field of TLRs during the 
following years resulted in the characterization and identification of a whole 
family of TLRs and many of their ligands. To date 10 functional TLRs in humans 
and 12 in mice have been discovered. Some of them are located on the cell-
surface whereas others operate as intracellular receptors in endosomal 
membranes. Toll-like receptor proteins are expressed by many cell types, such 
as macrophages, dendritic cells, epithelial cells and other immune cells, where 
every TLR is dedicated to detect a distinct set of microbial ligands. Table 2 
states ligands and cellular distribution of all 13 TLR proteins. In short, plasma 
membrane localized TLRs sense proteins and lipids, whereas those located in 
the membranes of endosomes are able to detect nucleic acids. 
Table 2 Ligands and localization of TLRs 
Adapted and modified from [88] 
Toll-like receptor Cellular distribution Ligand 
TLR1/2 heterodimer 
 
Monocytes and mast cells, 
eosinophils, basophils, 
dendritic cells 














NK cells dsRNA 
[93] 
TLR4 Macrophages and mast 
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Toll-like receptor Cellular distribution Ligand 




NK cells, dendritic cells, 
eosinophils, B cells 








Dendritic cells, eosinophils, 
basophils, B cells 
unmethylated CpG DNA 
[99] 
TLR10 (human only) Dendritic cells, eosinophils, 
basophils, B cells 
not determined 
TLR11 (mouse only) Macrophages, dendritic 
cells, epithelial cells 
Profilin  
[100] 




TLR13 (mouse only) not determined rRNA 
[102, 103] 
 
1.2.1 TLR structure and signaling 
TLRs belong to the family of type 1 transmembrane proteins. They are 
characterized by an extracellular domain composed of leucine-rich repeats 
(LRRs) creating a horseshoe-shaped figure. The cytoplasmatic tail in 
mammalian TLRs consists of a Toll/IL-1 receptor (TIR) domain [104]. Whereas 
the LRRs represent a scaffold responsible for recognition and binding of 






Fig. 2  Structure of the TLR protein 
The structure of TLR proteins is shown, using the example of TLR1 and TLR2 forming a 
heterodimer. Binding of specific ligands induces dimerization of two TLRs, bringing their TIR 
domains close together to initiate the intracellular signaling pathway. LRR = leucine-rich repeat, 
TIR = Toll/IL-1 receptor 
TLRs function as primary sensors of the immune system and are responsible 
for recognizing and responding to particular molecular pattern so called 
pathogen-associated molecular patterns (PAMPs) that are not naturally 
appearing in cells of healthy vertebrates. In order to identify and bind their 
specific ligands, TLRs form dimers, resulting in convergence of both the LRR 
and TIR region. Most TLRs act as homodimers to initiate the intracellular 
signaling pathway, however, TLR1 and TLR2 as well as TLR2 and TLR6 form 
heterodimers. Furthermore TLR heterodimerization of TLR4/6 with CD36 as a 
co-receptor has been described, promoting the activation of proinflammatory 
mediators [105]. Recent studies suggest heterodimerization of TLR2/4, which is 
thought to play a crucial role in inflammatory intracerebral hemorrhage [106]. 
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Murine TLR11 and TLR12, both able to detect T. gondii protein profilin, are 
newly also assumed to form heterodimers [101]. 
Binding of the ligand to the extracellular TLR site initiates dimerization of two 
single receptors. Dimerization is a prerequisite to activate the signaling cascade 
(Fig. 3) as it allows close interaction of the two intracellular TIR domains. 
However, in the case of TLR4, the accessory proteins MD-2 and CD-14 are 
necessary for the recognition of its ligand LPS (Table 2) and activation of TLR4. 
Once activated, the receptors’ TIR domains interact with both each other as well 
as with TIR domains of cytoplasmatic adaptor molecules. Mammalian TLRs use 
combinations of the following four different adaptor molecules to trigger the 
signaling pathway: TRIF (TIR domain-containing adaptor-inducing IFNβ), TRAF 
(TRIF related adaptor molecule), MyD88 (myeloid differentiation factor 88) and 
MAL (MyD88 adaptor-like). These molecules are able to initiate a cascade of 
events, including various enzymatic reactions, resulting in the activation of 
different transcription factors. With the exception of TLR3, MyD88 is a common 




Fig. 3 Signaling pathway of TLRs 
After ligand-induced dimerization, TLRs activate adaptor molecules (which are MyD88, MAL, 
TRIF and TRAM) in order to trigger gene transcription through transcription factors IRF, NFκB or 
AP-1. The cell consequently releases either antiviral type 1 interferons IFNα and IFNβ or 
proinflammatory cytokines. 
Endosomal TLRs, mostly targeted and activated by viral components, aim at 
recruiting transcription factor IRF (interferon regulatory factor). IRF is 
responsible for inducing the production of antiviral type 1 interferons IFNα and 
IFNβ. All other TLRs are in addition capable of activating both NFκB as well as 
AP-1 (activated protein 1). These transcription factors induce the expression of 
cytokine and chemokine genes, leading to secretion of proinflammatory 
cytokines and chemotactic factors [107]. 
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The intracellular signaling pathway of TLRs shows their remarkable capability to 
modify gene expression and immune responses, thereby being able to respond 
both to viral and bacterial threats as needed. 
1.2.2 TLRs and asthma pathogenesis 
Since PAMPS are thought to play a crucial role in the development of asthma, 
the role of TLRs as goal keepers of the innate immune system becomes an 
essential one. Consequently, research in the past decades has focused on the 
role of TLRs in the pathogenesis of asthma, atopy and other diseases.  
In order to find out, why some people are more likely to develop atopic diseases 
than others, genetic variations in TLR genes have been studied elaborately. 
Single nucleotide polymorphisms (SNPs) are a common type of such genetic 
variations within one population. A typical and frequent SNP, for example, is the 
replacement of the base cytosine with thymine in a genetic sequence. In fact, 
both protective and disease promoting modulations in TLR expression and 
genetic polymorphisms have been identified. 
In 2008, various genetic alterations in TLR genes and their association with 
childhood asthma were analyzed in a large German case-control study [34]. 
Interestingly, protective effects on atopic asthma could be demonstrated for 
SNPs in TLR1, TLR6 and TLR10, all capable of forming heterodimers with 
TLR2. These findings included increased levels of TLR mRNA as well as 
protein and Th1 cytokines. Secretion of IL-4, which is Th2 associated, was 
decreased [34], indicating a Th2 to Th1 shift. The protective role of TLR6 
activation in asthma and the resulting immunoregulatory beneficial effects were 
later also demonstrated in a HDM-induced mouse model of asthma by Moreira 
and colleagues [108]. 
A genetic variant in TLR2 was found to be associated with asthma susceptibility 
in farm children. Here, children carrying a certain allele in TLR2 were less likely 
to show asthma or atopic symptoms [109]. Another group investigating genetic 
polymorphisms in TLR2 and TLR4 demonstrated their association with disease 
severity, but not with the onset of allergic asthma [110]. 
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Genetic alterations in TLRs can also have adverse effects on asthma disease. 
A polymorphism in TLR4 was shown to be associated with a 4-fold higher risk to 
develop asthma in Swedish school children [111]. Increased expression of 
TLR2, 3 and 4 in airways was witnessed in victims of fatal asthma when 
compared to deceased control subjects [112]. An adverse effect on the 
development of atopic sensitization was demonstrated for a mutation in TLR2, 
relevantly impairing its receptor activity [113]. Evidence indicates that TLR5 
seems to play a major role in the onset of allergic asthma. Interaction with its 
ligand bacterial flagellin lays groundwork for allergic sensitization [114]. 
As mediators of inflammation, TLRs have great impact on development and 
severity of a broad variety of other diseases aside from asthma. TLR function 
and TLR polymorphisms influence sarcoidosis, tuberculosis and COPD but also 
non-pulmonary diseases such as type 1 diabetes, atherosclerosis, leprosy and 
intestinal disorders [115-121]. 
The complex involvement of different TLRs in the pathogenesis of asthma and 
other diseases is still not fully understood. Still, these research results allow 
optimistic conclusions regarding the development of potential drugs and 
therapies targeting TLRs. 
1.3 mRNA transcript therapy 
The potential and applications of gene therapy in the field of immunology have 
been of great interest in recent years. One strategy consists of utilizing 
replication-deficient viruses as vectors for therapeutic genes [122, 123]. Despite 
high transfection efficiency many concerns are associated with this method 
since genomic integration as well as unwanted immunostimulation and even 
induction of oncogenesis remain problematic [124]. Although nonviral-vector 
mediated gene transfer is thought to be less immunostimulative, insufficient 
gene transfer efficiency often leads to failure in clinical trials [125]. 
As a nonviral alternative, the delivery of mRNA has become a promising 
therapeutic approach during the past decade. Since mRNA doesn’t enter the 
nucleus, the risk of genomic integration and the role of the nuclear envelope as 
1.3 mRNA transcript therapy 
19 
a major obstacle are not relevant anymore. The possibility to administer mRNA 
repeatedly and its effectiveness even in non-dividing cells are two more central 
advantages. 
Still, also in vitro transcribed mRNA can trigger severe, undesirable immune 
responses. Besides its immunogenicity, mRNA in a conventional form is 
instable and labile, leading to early decay of the administered mRNA product in 
the target cell. However, with the discovery of the tool to chemically modify in 
vitro transcribed mRNA, both of these threats can be circumvented. With the 
incorporation of modified nucleotides such as pseudouridine [126] or 2-
thiouridine (s2U) and 5-methyl-cytidine (m5C) [127], mRNAs have a higher 
translational capacity and are less immunogenic. In fact, replacement of 25% of 
uridine and cytidine with s2U and m5C was able to hinder binding of mRNA to 
pattern recognition receptors such as TLRs 3, 7, and 8, therefore reduced 
activation of immune responses in vivo [127, 128]. 
The therapeutic potential and efficacy of modified mRNA has been successfully 
shown in the case of the lethal congenital disease of surfactant protein B (SP-B) 
deficiency. Here, administration of chemically modified SP-B mRNA showed life 
prolonging effect in vivo as it was able to restore therapeutic relevant levels of 
SP-B [127]. Delivery of mRNA-encoded T cell transcription factor Foxp3 
represents another successful example as a potential treatment strategy for 
pulmonary diseases. Administration of Foxp3 mRNA rebalanced T helper cell 
responses and significantly improved the asthmatic phenotype in two distinct 
murine models of allergic asthma [129]. 
mRNA-based gene transfer represents a promising therapeutic tool for diseases 
and genetic disorders with limited treatment options. As a relatively new drug 
class, in vitro transcribed mRNA is already investigated in a broad application 
area. Beyond replacement and substitution of proteins in vivo, chemically 
modified mRNA encoding nucleases is recently even opening new perspectives 
in the field of genomic engineering [130]. 
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1.4 Aim of this study 
The aim of this study is to investigate whether preventative treatment of mice 
with chemically modified Tlr1, 2 or 6 mRNA in an asthma model improves lung 
function and airway inflammation when compared to untreated controls. 
Consequently, it was examined how intrapulmonary application of combinations 
of chemically modified Tlr mRNA in vivo modulates immune response, lung 
function and inflammation in an HDM driven murine asthma model. 
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2 Materials and Methods 
2.1 Cloning Strategy 
Molecular cloning describes the process of moving any piece of DNA from one 
plasmid vector to another. Since restriction enzymes are playing a key role not 
only in isolating the DNA fragment but also in opening the plasmid vector, this 
method is also called “Plasmid Cloning by Restriction Enzyme Digest” or 
“Subcloning”. Once the specific piece of DNA, also referred to as “insert” or 
“Gene of Interest (GOI)”, has been successfully moved to the target vector, it 
can be easily amplified, stored, sequenced or used for expression studies. In 
the present study, the GOI Tlr1, 2 or 6, was cloned into the plasmid vector 
downstream of a T7 promoter and followed by a 120 bp polyA site. The T7 
promoter sequence represents the starting point for the T7 polymerase to start 
with RNA synthesis. The polyA tail consists of multiple adenosine 
monophosphates and protects the mRNA from enzymatic degradation. 
Furthermore the polyA tail facilitates transcription termination and translation 
[131]. In this study Tlr1, 2 and 6 genes initially were encoded on plasmid 
vectors with a pcDNA3.1 vector backbone (Table 3). Fig. 4 illustrates the steps 
of the cloning strategy to isolate Tlr inserts, move them to a standardized T7 
promoter-containing pVAX vector to finally produce mRNA via in vitro 
transcription (chapter 2.2). Tlr sequences are stated as supplemental 
information. 
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Fig. 4 Plasmid Cloning by Restriction Enzyme Digest 
The graph illustrates the cloning strategy to move a Tlr insert from a pcDNA3.1 plasmid vector 
to the target vector pVAX.A120 using the example of the Tlr1 insert. Labeled on the plasmid 
vectors are the promoter, the multiple cloning site (MCS) including various restriction sites 
(relevant restriction sites are indicated with scissors), the polyA tail (polyA), the Tlr insert and 
the resistance gene for ampicillin (Amp) or kanamycin (Kana) respectively. 
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Table 3 Original plasmids encoding mouse Tlr1, 2 and 6 





pcDNA3.1_Tlr1 Tlr1 2388 bp Ampicillin Stefan Bauer, 
Marburg 
pcDNA3.1_Tlr2 Tlr2 2300 bp Ampicillin Addgene, PI: 
Ruslan 
Medzhitov 
pcDNA3.1_Tlr6 Tlr6 2421 bp Ampicillin Stefan Bauer, 
Marburg 
 
2.1.1 Generation and transformation of chemically competent E. coli 
Generation of chemically competent E. coli 
Some bacteria are naturally capable of absorbing foreign DNA. It is, however, 
possible for other bacteria to gain this ability, called competence, via a special 
treatment. In this case the rubidium chloride method was used, which is a 
variant of the calcium chloride method yielding even higher competence [132].  
In order to generate chemically competent bacteria, 500 ml LB Medium were 
inoculated with 3 ml of the respective E. coli strain. Bacteria were then grown up 
to an optical density OD600=0.6-0.7 and afterwards centrifuged at 300 rpm for 
8 min at 4°C. After resuspending the cell pellet in prechilled Buffer RF1 (Table 
4), bacteria were incubated on ice for 15 min before centrifugation at 3000 rpm 
for 8 min at 4°C. The cell pellet was resuspended in Buffer RF2 (Table 5) and 
incubated on ice for another 15 min. The suspension was then resuspended 
again, aliquoted (100 µl) and immediately frozen in liquid nitrogen for storage at 
-80°C. 
Heat shock transformation of chemically competent E. coli 
Chemically competent E. coli were transformed with a plasmid (e.g. the initial 
plasmids, Table 3, or later the ligation product, 2.1.6) using the heat shock 
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method. 10 µl chemically competent E. coli were thawed on ice, gently mixed 
with ~10 ng of plasmid DNA and incubated on ice for 30 min. The suspension 
was then exposed to a heat shock at 42°C in water bath for 2 min, resulting in 
the bacteria membrane to release lipids and become porous. Furthermore the 
depolarization of bacterial cell membranes induced by heat shock leads to lower 
negative intracellular potential and facilitates therefore the uptake of negatively 
charged DNA into the competent cell. Following heat shock, bacteria were 
gently resuspended in 900 µl of SOC Medium and incubated on ice for 5 min. 
The suspension was then incubated for 2 hours at 37°C and 100 rpm vigorous 
shaking before centrifugation at 6000 rpm for 3 min. The supernatant was 
decanted and the pellet resuspended in the remaining fluid before being plated 
on agar plates containing the suitable antibiotic to select for the transformed 
bacteria. Agar plates were then incubated over night at 37°C to allow for growth 
of bacterial colonies. 
Table 4 Ingredients of Buffer RF1 
Buffer RF1  
Rubidium chloride 12 g 
Manganese chloride tetrahydrate  9.9 g 
Potassium acetate 1M 30 ml 
Calcium chloride dihydrate 1.5 g 
Glycerin 150 g 
Dist H2O ad 1000 ml 
Acetic acid ad pH 5.8 
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Table 5 Ingredients of Buffer RF2 
Buffer RF2  
Morpholino propanesulfonic acid 20 ml 
Rubidium chloride 1.2 g 
Calcium chloride  
dihydrate 
11 g 
Glycerin 150 g 
Dist H2O ad 1000 ml 
Sodium hydroxide ad pH 5.8 
 
2.1.2 Isolation of plasmid DNA 
Plasmid DNA was isolated from recombinant E. coli using either the Metabion 
Plasmid Miniprep Kit for small amounts or the QIAGEN Plasmid Mega Kit to 
receive large amounts of plasmid DNA. These methods were performed 
according to the manufacturer’s instructions as described in Table 3.  
In principle, both Kits are based on the method of bacterial lysis under alkaline 
conditions in the presence of SDS, first published by Birnboim and Doly [133]. 
In this method, plasmid DNA as well as chromosomal DNA is denatured in the 
presence of an alkaline buffer. Due to subsequent neutralization, plasmid DNA 
becomes selectively renatured. However, chromosomal DNA remains single 
stranded, thereby forming an insoluble precipitate. Soluble plasmid DNA then 
undergoes several purifications steps before being eluted and redissolved in TE 
Buffer. 
2 Materials and Methods 
26 
Table 6 Protocol to isolate plasmid DNA using a Mini or Mega Kit 
 Plasmid Mini Kit Plasmid Mega Kit 
Supplied by Metabion international AG, 
Martinsried, Germany 
Qiagen GmbH, Hilden, 
Germany 
Bacteria culture  3-5 ml 500 ml 
Harvest of 
bacteria 
The overnight culture was 
centrifuged at 5000 x g for 10 
min and the supernatant was 
decanted. 
The overnight culture was 
centrifuged at 6000 x g for 15 
min and the supernatant was 
decanted. 
Alkaline lysis The bacterial pellet was 
resuspended in 200 µl Buffer 
MX1, 250 µl of Buffer MX2 were 
added and inverted 4-6 times. 
The solution was incubated at 
room temperature for 1-5 min 
before addition of 350 µl MX3 
Buffer. 
Centrifugation at 10,000 x g for 
5-10 min. 
The bacterial pellet was 
resuspended in 50 ml Buffer 
P1, 50 ml Buffer P2 were 
added, inverted 4-6 times and 
incubated at room 
temperature for 5 min before 
addition of 50 ml prechilled 
Buffer P3. The solution was 
inverted 4-6 times and 
incubated on ice for 30 min 
before centrifugation at 
20,000 x g for 15 min. 
Equilibrate tips - 35 ml Buffer QT were applied  
on the tip. 
Binding 
mechanism 
After centrifugation the 
supernatant was carefully 
transferred into the column and 
centrifuged at 7000 x g for 1 
min. The flow-through was 
decanted. 
After centrifugation the 
supernatant was carefully 
transferred on the tip. 
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 Plasmid Mini Kit Plasmid Mega Kit 
Washing step (1) 500 µl Buffer WN were applied 
on the tip, centrifuged at 7000 x 
g for 1 min before application of 
700 µl Buffer WS. The solution 
was again centrifuged at 7000 x 
g for 1 min. 
Additional centrifugation at 
10,000 x g for another 3 min 
ensures removal of residual 
ethanol. 
200 ml of Buffer QC were 
applied on the tip. The flow-
through was discarded.  
Elution of DNA DNA was eluted with 30 µl 
elution buffer, incubated at 
room temperature for 3 min and 
centrifuged at 10,000 x g for 
3 min.  
This step was repeated with 
another 30 µl elution buffer. 
DNA was eluted with 30 ml of 
prewarmed (50°C) elution 
buffer. 
Precipitation - 20 ml isopropanol were added 
before centrifugation at 
15,000 x g for 30 min at 4°C, 
the supernatant was 
decanted. 
Washing step (2) - The pellet was washed with 7 
ml of 70% ethanol and 
centrifuged at 15,000 x g for 
30 min at 4°C, the 
supernatant was again 
decanted carefully. 
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 Plasmid Mini Kit Plasmid Mega Kit 
Drying step - The pellet was allowed to air 
dry and subsequently 
redissolved in 100 µl TE-
Buffer. 
 
2.1.3 Determining the concentration of nucleic acids 
The concentration of DNA or RNA in aqueous solution was determined by 
measuring the absorbance at λ = 260 nm using a nanophotometer. Further 
measurements at λ = 280 nm allow for detection of protein. For pure DNA 
samples with low protein contamination the ratio OD260/OD280 should yield 
results between 1.8 and 2.0 whereas pure RNA samples are required to yield 
an A260/230 ratio of not less than 2.0. 
2.1.4 Restriction enzyme digestion and DNA purification 
Restriction endonucleases are enzymes that cut DNA in a site-specific manner 
by catalyzing the hydrolysis of the DNA phosphodiester bond. Specific DNA 
sequences where restriction enzymes bind are usually four to eight bp long and 
often palindromic. Restriction enzymes produce either sticky ends by cutting 
double strand DNA in a staggered manner within the recognition site (resulting 
in single-stranded DNA ends) or blunt ends by cutting symmetrically with no 
overhangs being generated. 
In molecular biology, restriction enzymes are frequently used to analyze 
plasmid DNA, to cut out a certain sequence from a plasmid vector or to prepare 
DNA fragments for ligation. 
As soon as the plasmid vectors used for this study (pcDNA3.1_Tlr1, 
pcDNA3.1_Tlr2 and pcDNA3.1_Tlr6) were isolated and purified, control 
digestions and subsequent sequencing were performed to ensure that all 
plasmids contain the correct gene of interest. During control digestion 
procedure, the plasmid was digested with two restriction enzymes while the 
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expected length of digestion products was first calculated in silico using ApE 
software (ApE – A plasmid Editor vs2.0.45). In case of the gene of interest’s 
correct sequence and orientation the calculated bands should correspond to the 
bands appearing during gel electrophoresis (chapter 2.1.5). Control digestions 
were also performed after ligation procedure to verify correct orientation of the 
gene of interest. 
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Further restriction enzyme digestions in this study were performed in order to: 
- cut out the Tlr inserts from the pcDNA3.1 vector, 
- linearize the pVAX.A120 vector in order to ligate the Tlr gene into the 
target vector and 
- finally linearize the pVAX.A120_Tlr1, 2 or 6 vectors for subsequent 
mRNA production. 
In our study the protocol described in Table 7 was used to perform restriction 
enzyme digestions. Table 8 states the specific restriction enzymes used in this 
study. 
Table 7 Standard protocol for restriction enzyme digestion 
Reagent Volume Supplier 
Plasmid DNA equal to ~500ng Self generated 




1 µl per enzyme New England Biolabs Inc., 
Ipswich, UK 
H2O  ad 50 µl  
Incubation  1-2 hours at 37°C  
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Table 8 Application of different restriction enzymes for cloning procedure 
Intention Restriction Enzyme Supplier 
Control digestion of all pcDNA3.1 
plasmids containing a Tlr sequence 
NheI, NotI New England 
Biolabs Inc., 
Ipswich, UK  






SpeI HF, XhoI 
HindIII HF, XhoI 
New England 
Biolabs Inc., 
Ipswich, UK  
Opening of pVAX.A120 vector in 
order to insert a Tlr sequence 
EcoRI HF New England 
Biolabs Inc., 
Ipswich, UK  










Ipswich, UK  
Linearization of pVAX.A120 
containing the respective Tlr 
sequence in order to produce mRNA 
XhoI New England 
Biolabs Inc., 
Ipswich, UK  
 
After incubation at 37°C for one to two hours the digestion reactions were either 
heat inactivated, if the restriction enzyme allows doing so, or purified by using 
the NucleoSpin Gel and PCR clean-up kit (Machery-Nagel GmbH, Düren, 
Germany). This method purifies DNA fragments from enzymatic reactions by 
means of silica based membranes. DNA is first mixed with a chaotropic salt 
containing Buffer to allow the DNA to bind to the silica membrane of a spin 
column. Chaotropic salt furthermore helps to dissolve agarose in case of 
purifying DNA fragments out of agarose gels. Washing steps with ethanolic 
Buffer ensure removal of contaminations while subsequent DNA elution is 
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carried out under low salt conditions with alkaline Buffer. Purification of 
enzymatic reaction products was assayed according to the manufacturer’s 
instructions as described in Table 9. 
Table 9 Standard protocol to purify enzymatic reaction products 
Bind DNA One volume reaction solution was mixed with two volumes 
of Buffer NTI and applied on the spin column 
Centrifugation at 11,000 x g for 30 sec, flow-through discarded 
Washing step 
(performed twice) 
700 µl Buffer NT3 was applied on the column 
Centrifugation at 11,000 x g for 30 sec, flow-through discarded 
Drying step Centrifugation at 11,000 x g for 1 min 
Incubation at 70°C for 3 min to remove residual ethanol 
Elution Step 
(performed twice) 
15 µl of up to 70°C preheated Buffer NE was applied to the 
column and incubated at room temperature for 1 min 
before centrifugation for 1min at 11,000 x g.  
 
Correct digestion was subsequently verified by performing gel electrophoresis 
to analyze length of DNA fragments as described in 2.1.5. 
2.1.5 Gel electrophoresis and isolation of DNA fragments from agarose 
gels 
Mixtures of linearized DNA or RNA strands can be sorted and measured by 
agarose gel electrophoresis according to their size and charge.  
Agarose was dissolved in TAE buffer at the appropriate concentration (1% 
agarose for DNA and 1.5% for mRNA samples) in a microwave oven. 
Subsequently 5 µl of 1x GelRed (GelRed Nucleic Acid Stain, 10,000x in water) 
were added, a fluorescent dye to detect nucleic acids. The solution was then 
allowed to cool slightly and poured into a cast stuffed with a comb to create 
wells. Once the gel solid, the cast was filled with TAE buffer as the running 
buffer. Samples were mixed 6:1 with 6x loading dye to increase the density of 
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the samples and make them sink to the bottom of the well. DNA or mRNA 
samples were then loaded into the wells and electrophoresed at 70-100 V and 
400 milliampere. Furthermore a 1 kb DNA marker (GeneRuler; Thermo Fisher 
Scientific Inc., Waltham, USA) or ssRNA marker (New England Biolabs Inc., 
Ipswich, UK) was loaded into one additional well and co-electrophoresed with 
DNA samples. These markers contain fragments of standardized length. 
Comparison with these markers facilitates to determine the size of the samples 
on the gel. 
Bands on the gel were detected using UV light under a dark hood and 
documented by taking a picture using the Biostep Argus X1 software. 
For further use of DNA fragments the desired band was cut from the gel, 
weighed and purified using the High Pure PCR Product Purification Kit from 
Roche Diagnostics GmbH, Germany. Therefore the gel slice was dissolved in 
200 µl Binding Buffer for every 100 mg of agarose gel by vortexing briefly and 
incubating the solution for 10 min at 56°C. Further purification steps were 
performed as described in Table 9. 
2.1.6 Dephosphorylation and ligation 
Restriction enzymes used for this study (as stated in Table 8) all produce 
different sticky ends. However, in order to ensure standardized ligation 
conditions as described in Table 12, all DNA inserts and plasmid vectors require 
blunt ends. 
Therefore plasmid vectors and DNA inserts were treated with a VentR DNA 
Polymerase (New England Biolabs Inc.) as described in Table 10 prior to 
ligation. This polymerase fills in 5’ overhangs and removes 3’ extensions.  
Linearized plasmid vector pVAX.A120 was subsequently dephosphorylated at 
the 5’ end by treatment with an alkaline phosphatase according to the protocol 
described in Table 11 to prevent religation of the vector with itself. 
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Table 10 Protocol to generate blunt DNA fragments and vectors 
DNA According to rate of yield 
after purification 
 
dNTPs 1.0 µl PeqLab 
VentR Polymerase 0.5 µl New England Biolabs 
Inc. 
ThermoPol Buffer  
(10% of final volume) 
6.0 µl New England Biolabs 
Inc. 
H2O ad 60 µl  
Incubation 15 min at 72°C   
 
Table 11 Protocol for dephosphorylation of a DNA vector 
DNA vector Volume according to 





(10% of final volume) 
4.0 µl New England Biolabs 
Inc. 
Antarctic Phosphatase 1.5 µl New England Biolabs 
Inc. 
H2O ad 40 µl  
Incubation 15 min at 37°C  
Heat inactivation 5 min at 65°C  
 
DNA inserts were then included into the pVAX.A120 vector by means of an 
enzymatic reaction with a T4 DNA ligase. The enzyme ligase catalyzes the 
formation of phosphodiester bonds and therefore allows the joining of DNA 
double-strands. 
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In the presented work the ligation calculator from www.insilico.uni-
duesseldorf.de/Lig_Input.html was used to calculate the amount of insert while 
several vector to insert ratios were tested, such as 1:5, 1:10 and 1:20. 
Table 12 Protocol for ligation 
Plasmid vector pVAX.A120 10 ng  
DNA insert depending on vector to 
insert ratio and size of insert 
 
T4 DNA Reaction Buffer  
(10% of final volume) 
1 µl New England Biolabs 
Inc. 
T4 DNA Ligase 1 µl New England Biolabs 
Inc. 
H2O ad 10 µl  
Incubation  Overnight at 16°C  
 
After ligation the samples were finally inserted in bacteria using the heat shock 
transformation method. Plasmids were again isolated and checked for insertion 
of the correct plasmid: only inserts that were included into the plasmid vector in 
correct strand orientation during ligation can result in correct triplets in 
subsequent translation in 3’-5’ direction. For this purpose, plasmids from several 
bacterial clones were isolated and checked for correct sequence via restriction 
enzyme digestion (2.1.4) and additional sequencing (2.1.7) for final validation. 
2.1.7 Sequencing 
In order to verify DNA sequences of plasmid vectors or inserts, DNA fragments 
with correspondent primers (Table 13) were send to GATC Biotech, Konstanz, 
Germany, where all sequencing analysis for this study was carried out. Primers 
were designed in silico using the software http://primer3.ut.ee/ and purchased 
from Metabion GmbH, Martinsried, Germany. 
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With ApE software, sequence data in .seq or .ab1 format was afterwards 
analyzed and compared to original sequences of plasmid vectors and Tlr gene 
sequences as indicated at www.ncbi.nlm.nih.gov. 
Table 13 Primers used for sequencing in this study 
Sequencing of original plasmid vectors was performed using primers stated in (A). The primers 
to verify the sequences of final pVAX.A120 plasmid vectors containing Tlr sequences are stated 
in (B). All primers are stated in 5’-3’ direction.  
A Plasmid Gene Forward  Reverse  
pcDNA3.1_Tlr1 Tlr1 CMV fwd BGH rev 
pcDNA3.1_Tlr2 Tlr2 CMV fwd BGH rev 
pcDNA3.1_Tlr6 Tlr6 CMV fwd BGH rev 
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2.2 In vitro transcription of chemically modified mRNA 
T7 promoter-containing pVAX.A120 vectors encoding for Tlr1, 2 and 6 were 
linearized via restriction enzyme digestion as described in chapter 2.1.4 and 
transcribed in vitro into chemically modified mRNA, incorporating 25% 2-Thio-
UTP and 25% 5-Methyl-CTP using the T7 MEGAscript kit (Ambion). 
The T7 polymerase is a highly promoter-specific RNA polymerase originating in  
E. coli bacteriophages, that transcribes DNA only downstream a T7 promoter 
[134]. Double stranded DNA is separated and unwinded to allow for 
complementary base pairing on the codogenic strand. 
Because high amounts of mRNA were required for in vitro and in vivo studies, 
all mRNA transcriptions were performed as 5x applications using 5 µg linearized 
vector DNA and 10 µl enzyme mix (Table 14) for each reaction. Since precision 
and cleanliness is crucial when working with mRNA, it has been taken care of 
an RNase free environment and lab space at all times.  
In order to achieve low immunogenicity in vivo while at the same time achieving 
high gene transfer efficiency and stability an Anti Reverse Cap Analog (ARCA, 
TriLink Bio Technologies) and modified nucleotides were incorporated in terms 
of replacing 25% of UTP with 2-Thio-UTP and 25% of CTP with 5-Methyl-CTP 
[127]. The exact GTP to ARCA ratio is not defined, leading to overall higher 
amounts of guanine nucleotides in the reaction volume [126]. 
Before use, nucleotides were thawed on ice and reaction buffer at room 
temperature. Nuclease-free DEPC water was used for dilutions. All ingredients 
were pipetted carefully in a nuclease free reaction tube and incubated at 37°C 
for 2-3 hours to allow for mRNA transcription of the T7 polymerase. 
Subsequently 5 µl Turbo-DNase (MEGAscript T7, Ambion) was added and 
incubated at 37°C for 15 min to ensure degradation of residual DNA. 
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Table 14 Protocol for mRNA in vitro transcription of a T7 promoter containing 












ATP 10  75 7.5 100 MEGAscript T7, 
Ambion 
CTP 7.5 75 5.625 75 MEGAscript T7, 
Ambion 
m5CTP 1.9 100 1.9 25 TriLink 
BioTechnologies 
UTP 7.5 75 5.625 75 MEGAscript T7, 
Ambion 
s2UTP 1.9 100 1.9 25 TriLink 
BioTechnologies 










10     MEGAscript T7, 
Ambion 
Plasmid DNA equal to  
5 µg 
    
Enzyme Mix 10     MEGAscript T7, 
Ambion 
DEPC water ad 100      
 
2.3 Cultivation and transfection of A549 and MLE12 cells 
39 
The MEGAclear kit (Ambion) was used for clean-up and purification of mRNA 
samples based on the principle of silicate based membranes [135]. To each 
reaction tube 350 µl binding solution concentrate and 250 µl 100% ethanol were 
added, the sample was supplied into a filter cartridge placed into a collection 
tube and centrifuged at 13,000 rpm for 30 sec. This was followed by a twofold 
performed washing step with 500 µl wash solution and centrifugation at 13,000 
rpm for 30 sec each to remove residual nucleotides that haven’t been 
incorporated during transcription. An additional centrifugation at 13,000 rpm for 
30 sec ensured complete removal of remnants of wash solution and ethanol. 
New RNase-free tubes were now used for elution of mRNA using 42 µl elution 
solution, incubation at 70°C for 10 min and centrifugation at 13,000 rpm for 1 
min. The elution step was repeated with another 42 µl elution solution to 
maximize the yield of mRNA. The reaction was then placed on ice, 
concentration of mRNA was measured and the samples were stored at -80°C. 
To check the mRNA for correct length gel electrophoresis was performed as 
described above (chapter 2.1.5) with the following changes in procedure: for 
mRNA samples, 1-3 µg mRNA were mixed with 2 µl 2x RNA Loading Dye (New 
England Biolabs Inc., Ipswich, UK) and filled up with DEPC water ad 12 µl. The 
mixture for 10 µl mRNA ladder was prepared using 2 µl ssRNA ladder (New 
England Biolabs Inc., Ipswich, UK), 3 µl DEPC water and 5 µl 2x Loading Dye. 
Samples were loaded onto a 1.5% agarose gel and electrophoresis was 
performed at 80 Volt and 400 milliampere until a sharp band was detectable. 
2.3 Cultivation and transfection of A549 and MLE12 cells 
Mouse transformed epithelial cells (MLE 12; deposited by ATCC American Type 
Culture Collection, Manassas, USA) and Human alveolar type 2 epithelial cells 
(A549; deposited by CLS Cell Line Service, Eppelheim, Germany) were grown 
in cell culture medium consisting of Dulbecco’s Modified Eagle Medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS) and 1% penicillin-
streptomycin. Cells were cultured in a 175 cm2 tissue culture flask under 
standardized conditions at 37°C and 5% CO2.  
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Both cell types grow adherent and were splitted when reached 90% confluency. 
For this purpose the old medium was decanted, cells were washed with 10 ml 
PBS before being incubated with EDTA solution containing 0.25% trypsin at 
37°C to allow for adherent cells to detach. Preheated DMEM stopped trypsin 
activity and cells were either used for experiments or seeded at different 
dilutions in order to grow again. 
Transfection with Lipofectamine 2000 
Lipofection is a transfection procedure using liposomes as vehicles to inject 
genetic material into eukaryotic cells. Cationic lipids interact spontaneously with 
anionic genetic material forming lipid-DNA or –RNA complexes, able to enter 
cells by fusion with their plasma membrane [136]. In doing so, lipofection is 
greater than 5- fold more effective than other transfection techniques, e.g. the 
calcium-phosphate or the DEAE-dextran transfection technique [137]. 
In the presented work Lipofectamine 2000 (Invitrogen Life Technologies 
Corporation) was used as a transfection reagent, containing 1 mg/ml neutral 
and kationic lipids. 
One day prior to lipofection procedure, cells were seeded in a 24-well plate with 
a concentration of 100,000 cells and 500 µl medium per well. At the time of 
transfection cells should be 80-90% confluent. Each well was transfected with 
an amount of 0.5 µg mRNA (modified after Kormann, Depner et al. 2008). The 
transfection rate depends not only on cell lines, cell density and amount of 
nucleic acids [136] but also on incubation times [138]. Before transfection, cells 
received 400 µl fresh medium without antibiotics. Two reaction tubes for each 
well were prepared. In tube 1) 0.5 µg mRNA was filled up with Opti-MEM 
medium ad 50 µl, whereas tube 2) contained 2 µl Lipofectamine and 48 µl Opti-
MEM. Both tubes were incubated at room temperature for 5 min. Carefully each 
solution from tube 1) (mRNA) was added to respective tube 2) (Lipofectamine) 
and incubated at room temperature for 20 min to allow for generation of lipid-
mRNA complexes. This solution was then slowly pipetted into cell culture wells. 
Cells were again incubated at 37°C and 5% CO2. New medium was supplied 
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after 12 hours. Cells were stained and subjected to flow cytometry after 24 
hours or 48 hours respectively. 
2.4 Flow cytometry 
Flow cytometry offers a method for quantitative analysis of cells in suspension 
[139]. The fundamental concept is based on scattered and fluorescent light. 
Cells or other microscopic particles in suspension pass by a laser beam and 
interact with the light. Light scatter as well as fluorescent scatter can be 
measured and are then detected separately. Whereas light scatter allows to 
determine not only size (via forward scatter, FSC) but also granularity (via side 
scatter, SSC) of the cell, fluorescent scatter can tell about cell specific 
components in case they have been stained with a fluorescent dye prior to flow 
cytometry. Various cell types and also dead cells can be distinguished 
according to their different physical properties. The use of different wavelengths 
of the laser stream enables the detection of various fluorescent signals. Usually 
flow cytometry data are shown as a density plot or on a histogram. On a density 
plot, each dot represents an individual cell while green and yellow areas 
indicate large number of events. On histograms, cell types can be analyzed 
separately and plotted as cell count on the y-axis versus fluorescence intensity 
on the x-axis. 
In this study, flow cytometry was used to measure surface expression of 
TLR1, 2 and 6 on MLE12 and A549 cells in vitro as well as on lung and spleen 
tissue cells in vivo. This method was further used to quantify and differentiate 
different immune cells isolated from lung and spleen tissue after in vivo 
treatment with Tlr mRNA. Antibodies used for in vitro and in vivo experiments of 
this study are stated in Table 15. 
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Table 15 Antibodies to stain cells from whole lung and spleen tissues for 
T cells, T regs, B cells, eosinophils and dendritic cells 
Antibody Supplier 
Anti-mouse TLR1-PE goat IgG R&D Systems 
Anti-mouse TLR2-FITC mouse IgG1 BioLegend 
Anti-mouse TLR6-APC rat IgG2A R&D Systems 
Anti-mouse F4/80-Pacific Blue rat IgG2A BioLegend 
Anti-mouse Siglec F-PE rat IgG2A BD Pharmingen 
Anti-mouse CD19-PerCP/Cy5.5 rat IgG2A BioLegend 
Anti-mouse CD11b-PE.Cy7 BD Pharmingen 
Anti-mouse CD11c-APC/Cy7 hamster IgG1 BD Pharmingen 
Anti-mouse Ly6G-APC rat IgG2b eBioscience 
Anti-mouse CD3e-Brilliant Violet rat IgG2b BioLegend 
Anti-mouse CD4-APC rat IgG2b eBioscience 
Anti-mouse CD25-PE/Cy7 rat IgG1 eBioscience 
Anti-mouse Foxp3-PE rat IgG2a eBioscience 
Rat IgG2a-PE eBioscience 
Foxp3 Fix/Perm Buffer Set BioLegend 
 
For in vitro experiments, A549 and MLE12 cells were prepared for flow 
cytometry analysis either 24 hours or 48 hours after transfection procedure. 
Cells were washed, detached from culture flasks as described above (chapter 
2.3), washed again, centrifuged at 400 x g for 10 min, supernatant was 
decanted and cells were resuspended in 100 µl FACS buffer (1 x PBS with 
0.1% BSA and 0.02% NaN3) and stored on ice. Per 1 x 10
6 cells and 100 µl 
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volume, cells were stained with either 2 µl Anti-mouse TLR2, 8 µl Anti-mouse 
TLR1 or 8 µl Anti-mouse TLR6 per tube depending on their previous mRNA 
treatment. Non-transfected cells served as controls and were therefore pooled 
and stained with antibodies as mentioned above. An additional sample 
remained unstained as a control. All cells were incubated at 4°C for 30 min, 
washed and resuspended in 100-200 µl FACS buffer before being subjected to 
flow cytometry. 
 
Fig. 5 Gating strategy for in vitro experiments to detect TLR expression in 
MLE12 and A549 cells 
In the dot plot (A) cells were first gated for living cells by forward scatter (FSC) and side scatter 
(SSC). Histograms (B and C) only include living cells. Blue peaks indicate TLR expression on 
untransfected controls whereas red peaks show the positive dataset of increased TLR 
expression after transfection with chemically modified Tlr mRNA. Representative graphs of 
A549 cells after transfection with Tlr1 (B) and Tlr2 (C) mRNA are shown. 
For in vivo experiments lung and spleen cells were isolated and stained as 
described in chapter 2.6. Cells from each mouse were separated whereas the 
first part (a) was stained for TLR1, 2 and 6 expression, the second part (b) for 
differential cell analysis and the third part (c) for Foxp3 as a marker for CD4+ 
regulatory T cells. Each tube contained 500,000 cells in 100 µl FACS buffer and 
was incubated for 30 min at 4°C after the respective antibody mix was added. 
Cells were subsequently washed, centrifuged, resuspended in 100 µl FACS 
buffer and subjected to flow cytometry. 
In order to investigate the expression of TLR1, 2 and 6 in lung and spleen 
tissue, cells were stained with a mixture of 10 µl Anti-mouse TLR1, 2 µl Anti-
mouse TLR2 and 10 µl Anti-mouse TLR6 per tube. 
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Fig. 6 Gating strategy for in vivo experiments to analyze TLR expression on 
lymphocytes, monocytes, PBMCs and neutrophils 
Cells from whole lung and spleen tissue were isolated and stained for TLR1, 2 and 6. On the 
density plot. (A) cell types were analyzed separately and then plotted on histograms as cell 
count on the y-axis versus TLR fluorescence (PE for TLR1 (C), FITC for TLR2 (B) and APC for 
TLR6 (D)) on the x-axis. The red peak indicates the data of an unstained control, the black peak 
shows the data of stained samples. According to unstained samples, Marker (M1) was set as a 
threshold to define positive events. 
Cell infiltration in lung and spleen tissue was differentially analyzed by adding 
the antibody mixture stated in Table 16 to each tube. 
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Table 16 Antibodies for cell differentiation by flow cytometry 
Antibody Volume 
Anti-mouse F4/80 0.5 µl 
Anti-mouse Siglec F 0.5 µl 
Anti-mouse CD19 0.25 µl 
Anti-mouse CD11b 0.25 µl 
Anti-mouse Ly6G 6 µl of a 1:100 dilution 
Anti-mouse CD3 2.5 µl 
Anti-mouse CD11c 1 µl of a 1:10 dilution 
FACS buffer ad 50 µl 
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Fig. 7  Flow cytometry gating strategy for in vivo experiments to detect T cells, 
B cells, eosinophils and dendritic cells from lung and spleen tissue 
A: Single cells and live cells were first identified by forward scatter (FSC) and side scatter 




cells. C: Cells other than 
macrophages were fragmented into myeloid (SSC and CD11b
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In order to indentify regulatory T cells (Tregs), the fraction of CD4+ CD25+ 
Foxp3+ positive cells was measured via intra- and extracellular staining. 
Prepared cells were first stained for extracellular CD4 and CD25 (1 µl Anti-
mouse CD4 and 3 µl Anti-mouse CD25 per tube). After incubation (30 min, 4°C) 
cells were washed, resuspended in 150 µl FACS buffer and 200 µl 1% Foxp3-
Fix/Perm solution to fix cells prior to permeabilization treatment. After incubation 
at room temperature for 20 min in the dark, the solution was centrifuged and the 
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supernatant was decanted. Fixed cells were resuspended in 200 µl 1% 
Foxp3Perm Buffer to permeabilize the cells to allow for the fluorochrome 
reaching the interior of the cell. This solution was again incubated 15 min at 
room temperature in the dark, washed and resuspended in 50 µl Foxp3Perm 
Buffer. Cells were then stained with either 5 µl Anti-mouse Foxp3 or 5 µl Rat 
IgG2a as an isotype control. After another 30 min of incubation cells were 
washed and resuspended in 100 µl FACS Puffer for subsequent analysis via 
flow cytometry. 
 
Fig. 8 Gating strategy for in vivo experiments to detect CD4+ CD25+ Foxp3+ 
Tregs 
In a density plot for SSC versus FSC cells were gated for living cells (A). Living cells were then 
gated into CD4
+
 cells (B). These were further gated for CD25 and Foxp3 fluorescence. Isotype 













 Tregs (D), shown in the upper right quadrant of Foxp3 gate. 
Cells were analyzed on FACS Calibur using CellQuest software. Data was 
further interpretated and analyzed with FACSDiva (vs 6.1.3) software for in vitro 
experiments. FCS Express and FlowJo software were used to analyze in vivo 
data. 
2 Materials and Methods 
48 
2.5 Animal experiments 
Six- to eight-week-old female BALB/c mice were purchased from Charles River 
Laboratories. Mice were kept under standardized specific pathogen-free 
conditions and maintained on a 12-h light-dark cycle. Food, water as well as 
nesting material were provided ad libitum. All animal experiments were 
approved by the local ethics committee and carried out according to the 
guidelines of the German Law for the Protection of Animals.  
Intratracheal (i.t.) procedures were carried out under antagonizable anesthesia 
with a mixture of medetomidine (0.5 mg/kg), midazolam (5 mg/kg) and fentanyl 
(50 µg/kg). After treatment antidot was injected subcutaneously consisting of 
atipamezol (50 µg/kg), flumazenil (10 µg/kg) and naloxon (24 µg/kg). 
At the age of 10-12 weeks, mice received their first i.t. treatment of the injection 
schedule (Fig. 18). This schedule was adapted from Mays et al. [129] and 
modified to enable a preventative treatment with Tlr mRNA prior to HDM 
exposure. Mice received either four instillations of Tlr mRNA combinations 
followed by three instillations of HDM extract (Dermatophagoides 
pteronyssinus, GREER laboratories, Lenoir, NC, USA), PBS instead of mRNA 
followed by HDM exposure as positive controls or PBS only as negative 
controls. Furthermore, mice were treated with Tlr mRNA followed by PBS 
administration instead of HDM, to observe whether mRNA application on its 
own may modify the asthmatic outcome in vivo (Table 17). 
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Table 17 Groups of mice and their respective treatment following the injection 
schedule as stated in Fig. 9 
Group n = Treatment 
day -17, -14, -10, -7  
 
day 0, 7, 14 
Endpoint 
 
1 9 Tlr1/2 mRNA HDM day 15 
1.1 3 Tlr1/2 mRNA PBS 
2 9 Tlr2 mRNA HDM 
2.1 3 Tlr2 mRNA PBS 
3 9 Tlr2/6 mRNA HDM 
3.1 3 Tlr2/6 mRNA PBS 
4 9 PBS HDM 
4.1 9 PBS PBS 
 
Fig. 9 Timeline illustrating the injection schedule of the HDM induced mouse 
model of asthma 
Mice were treated intratracheally and received either 100 µg HDM, 20 µg mRNA per Tlr or PBS 
as a control. 
2.6 Lung and spleen cell isolation  
At experimental endpoints, mice were euthanized using 120 mg/kg 
pentobarbital sodium. Spleens were removed and squeezed through a 70 µm 
cell strainer while rinsing the sieve with 50 ml cold PBS. Lungs were removed 
and each left lobe was fixed in phosphate buffered formaldehyde and further 
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treated as described in chapter 2.11. Right lungs were shredded, incubated in 1 
ml digestion solution (Table 18) for 1-2 hours at 37°C and subsequently 
squeezed through a 70 µm cell strainer rinsed with 50 ml cold PBS. Spleen and 
lung cells were centrifuged at 400 x g for 10 min before cell pellets were 
resuspended in 5 ml lysis buffer and incubated for 5 min at room temperature. 
50 ml PBS per sample were added and cells were centrifuged again at 400 x g 
for 10 min. The cell pellet was finally resuspended in 3 ml PBS and live cells 
were counted.  
Table 18 Solution to digest lung tissue prior to lung cell staining for flow 
cytometry analysis 
Digestion solution  Final concentration Supplier 
Collagenase Type 1 1 mg Life technologies 
Dispase 1 mg Corning 
DNase  1% (500 U) EPICENTRE Biotechnologies 
 
2.7 Lung function test 
At the predetermined endpoint of the study, airway resistance in response to 
methacholine (MCh, acetyl-β-methylcholine chloride; Sigma-Aldrich) was 
determined from n=6 mice per group using the model of the isolated, perfused 
and ventilated lung (IPL) [129]. 
Mice were deeply anaesthetized and toe reflex tests were performed to 
measure the depth of anaesthesia. The animal was fixed in a thorax chamber in 
supine position. The Trachea was cannulated for mechanical ventilation with 90 
breaths per minute by negative pressure ventilation between -2.8 cm H2O (end-
expiratory) and -8.5 cm H2O (end-inspiratory). Furthermore hyperinflation (-25 
cm H2O) was performed every 5 minutes to prevent atelectases of the lungs. 
After a laparatomy the diaphragm was dissected and heparin 500 IE/100g was 
injected into the right ventricle of the heart. The renal artery was then cut 
resulting in the mouse bleeding to death. The lower half of the body was 
2.7 Lung function test 
51 
discarded and the thorax opened to cannulate the pulmonary artery and vein. 
Subsequently the chamber was closed and the pulmonary vessels were 
perfused at a constant flow rate (1 ml/min) in a nonrecirculating manner with a 
4% hydroxyethyl starch containing perfusion buffer (Fig. 10). After a 20-minute 
equilibration period, the lungs were perfused with increasing concentrations of 
MCh (0.1 μM, 1 μM, 10 μM, and 100 μM) for 10 min each, separated by a 20-
minute washout period with buffer. 
 
Fig. 10 Lung function and airway resistance was measured using the ex vivo IPL 
method 
The trachea was mechanically ventilated through an air inlet in a vacuum chamber. The 
pulmonary artery and vein were cannulated and perfused with buffer. 
The mean resistance values were calculated from the last 30 seconds of each 
10-minute MCh exposure for statistical analysis. During this whole process, 
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Lung function parameters were analyzed automatically by HSE-HA Pulmodyn 
W Software (Harvard Apparatus). 
2.8 Enzyme linked immunosorbent assay (ELISA) 
Cytokines in BALF supernatant collected from mice at the predetermined 
endpoint of the study were assayed in triplicates by ELISA for IL-5, IL-13, IFNγ 
and CCL17 (Table 19) according to the manufacturer’s instructions. Briefly, 96-
well plates were precoated with antibody solution and then loaded with 
undiluted samples. After overnight incubation at 4°C chemokines were detected 
by horseradish peroxidase-linked antibodies and optical density values were 
measured in a microplate reader. Concentrations of chemokines were then 
calculated from standard curves. 
Table 19 Chemokines investigated in this study via ELISA and suppliers of 
respective kits 
Chemokine Detection limit  
(minimum-maximum) 
Supplier 
IL-5 4 – 500 pg/ml eBioscience 
IL-13 4 – 500 pg/ml eBioscience 
IFNγ 15 – 2000 pg/ml eBioscience 
CCL17 7.8 – 500 pg/ml R&D Systems 
 
2.9 Cytokine multiplex panel 
Cytokines in BALF supernatant were additionally analysed for IL-2, IL-4, IL-5, 
IL-10, IL-12p70, IL-17A, IFNγ and TNFα using a mouse cytokine multiplex panel 
according to the manufacturer’s instructions (Bio-Plex Cytokine Assay, Bio-Rad 
Laboratories, USA). The Bio-Plex suspension array allows the detection of 
multiple cytokines in a single well while only a relatively small sample volume is 
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required. This technology combines the principles of flow cytometry and a 
sandwich immunoassay, using colored beads instead of a coated well [140]. 
In brief, antibodies directed to the cytokines of interest are covalently coupled to 
fluorescent beads. These antibody-coupled beads are allowed to react with an 
unknown amount of cytokines in any sample dilution. An additional analysis of 
samples containing a known amount of cytokines allows to establish a standard 
curve. After several washing steps, a specific detection antibody and finally 
streptavidin-PE is added to the reaction mixture. Lasers in the flow-based array 
system excite the fluorochromes and thereby detect and quantify the specific 
cytokine reaction in each well. Cytokine concentrations are automatically 
calculated by Bio-Plex Manager Software. 
2.10 Differential cell count of murine bronchoalveolar lavage (BAL) 
Bronchoalveolar lavage (BAL) fluid was obtained at the time of sacrifice. Gently, 
the trachea was dissected and carefully cannulated with a needle. Lungs were 
lavaged twice with 1 ml prechilled PBS. Each BALF sample was then 
centrifuged for 10 min. at 500 x g. The supernatants were collected and stored 
at -20°C for cytokine analysis. Cell pellets were subsequently resuspended in 
PBS and diluted with PBS 1:5. From this dilution a volume of 300 µl was used to 
prepare monolayer smears by cytocentrifugation at 800 rpm for 10 min at 4°C. 
The smears were then stained with May-Grünwald-Giemsa. Differential cell 
counts of BALF were performed from at least 100 cells per smear and analyzed 
using a Zeiss Axio Imager.M2 with the AxioCam MRc camera. Standard 
hemocytologic criteria were used to classify the cells as neutrophils, 
eosinophils, lymphocytes, macrophages and monocytes (Fig. 11). 
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Fig. 11 Representative smear of BAL cells after cytospin procedure 
Black arrows indicate different cell types of a BAL fluid sample. 
2.11 Histopathology of murine lung tissue 
In order to analyze inflammation and mucus production in lung tissues, each left 
lung was removed at the predetermined endpoint of the study. Lungs were fixed 
in Histofix (4.5%, Carl Roth) overnight and embedded in paraffin. Slices (4 µm) 
were stained with either H&E or periodic acid-Schiff (PAS). The samples were 
examined using a Zeiss Axio Imager.M2 with the AxioCam MRc camera. 
Multiple photographs were taken of the primary airway, perivascular and 
interstitial areas. Inflammation and infiltration of lung tissue was evaluated on 
H&E stained sections. Mucus-producing PAS-positive goblet cells were 
quantified in percent of counted cells (determined by visible nuclei). 
2.12 Statistical analysis 
Statistical significance of differences was defined as P<0.05 and denoted with 
asterisks: *0.05, **0.01 and ***0.001. Statistical analysis and generation of 
figures presented in this thesis were performed using GraphPad Prism 6.0 
(GraphPad Software, San Diego, California) and SPSS Statistics Version 22 
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(IBM). Unless stated otherwise, data were statistically analyzed using Kruskal-




3.1 Cloning of murine Tlrs for mRNA transcript therapy 
3.1.1 Plasmidisolation and cloning of Tlr1, 2 and 6 into a pVAX.A120 
plasmid vector 
In order to receive high amounts of plasmid vectors containing the respective 
Tlr genes, pcDNA3.1 plasmids encoding for murine Tlr1, 2 or 6 were inserted 
into E.coli via heat shock transformation. Subsequently plasmids were isolated 
and Tlr gene inserts were cut out via restriction enzyme digestion. To further 
isolate the Tlr insert and check it for correct length of sequence, a gel 
electrophoresis and gel isolation were performed. Correct isolation of the Tlr2 
insert is shown in Fig. 12 representatively for all Tlr inserts. 
 
Fig. 12 Isolation of the Tlr2 fragment from an agarose gel 
(A) A pcDNA3.1 plasmid incorporating an Tlr2 insert was digested with SpeI HF and XhoI and 
run on an agarose gel. The 2300 bp Tlr2 fragment was identified by comparing the fragment of 
interest to the DNA ladder on the left and the previously extracted Tlr2 fragment on the right. 
The desired band was removed with a razor blade, (B) the white arrow indicates the empty 
space after removal. 
Following the isolation procedure, Tlr1, 2 or 6 inserts were ligated into the 
pVAX.A120 plasmid vector. 
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3.1.2 Validation of the correct structure and sequence of pVAX.A120_Tlr 
plasmids 
The final sequence of the pVAX.A120_Tlr plasmid construct after ligation was 
validated via control restriction enzyme digestion, gel electrophoresis (Fig. 13) 
and additional sequencing (Fig. 14). 
 
Fig. 13 Gel electrophoresis of pVAX.A120_Tlr2 plasmids from various bacterial 
clones after restriction enzyme digestion 
In case of successful intake of the Tlr insert into pVAX.A120, restriction enzyme EcoRI HF 
produces fragments of 4191 bp and 1268 bp of length. In the picture above white arrows 
indicate plasmids from bacterial clones number 54 and 57 showing the desired pattern and thus 




Fig. 14 Sequence data of plasmids was analyzed using ApE software 
Representative data from Tlr1 sequence is shown. (A) Alignment to compare the original Tlr 
sequence (a) as stated at www.ncbi.nlm.nih.gov to the sequencing results of Tlr1 inserted into 
the pVAX.A120 plasmid vector (b). Here, the beginning of the coding sequence is shown, with 
the black arrow indicating the start codon. Mismatches or mutations did neither occur in this nor 
in the following part of the sequence (data not shown). (B) The electropherogram illustrates the 
origin of the same Tlr1 coding sequence, showing distinct signal amplitudes without mutations 
or overlaps. 
3.2 Generation of chemically modified Tlr mRNA 
3.2.1 In vitro transcription of chemically modified Tlr1, 2 and 6 mRNA 
Chemically modified mRNA incorporating 25% 2-Thio-UTP and 25% 5-Methyl-
CTP was produced via in vitro transcription. After the transcription process, a 
gel electrophoresis was performed with 1-3 µg mRNA of each sample to ensure 
the correct length of the mRNA strand. Fig. 15 presents Tlr1, 2 and 6 mRNA 
samples of correct length after gel electrophoresis. 
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Fig. 15 Gel electrophoresis of Tlr1, 2 and 6 mRNA after in vitro transcription 
mRNA samples were run on an agarose gel. Bands appear as expected at approximately 
2591bp for Tlr1 mRNA, 2570bp for Tlr2 mRNA and 2625bp for Tlr6 mRNA. 
3.2.2 Validation of TLR1, 2 and 6 expression in vitro after transfection of 
Tlr mRNA  
Tlr1, 2 and 6 mRNA was transfected into A549 and MLE12 cells, in order to 
check the mRNA for correct function. Subsequently, cells underwent lipofection 
procedure and were subjected to flow cytometry to measure TLR expression 
after 24 hours or 48 hours respectively. TLR expression detected 48 hours post 
transfection (data not shown) was markedly reduced and cell numbers were 
decreased when compared to samples incubated only 24 hours after 
transfection procedure and have therefore not been analysed further. The steep 
increase in RFP positive cells after transfection of RFP mRNA is shown in Fig. 




Fig. 16 TLR expression in A549 cells after transfection with Tlr mRNA 
A549 cells were transfected with Tlr1, 2 or 6 mRNA, harvested and stained after 24 hours and 
subjected to FACS analysis. (A) Transfection with RFP mRNA served as a control and 
confirmed successful lipofection procedure by a steep increase in RFP
+





 cells were elevated when compared to untransfected controls. (C) Expression of TLR2 
increased markedly after transfection with respective mRNA. Data are represented as means ± 
SEM. 
A549 cells showed higher levels of cells positive for TLR1 after transfection of 
Tlr1 mRNA when compared to untreated control cells (Fig. 16B). Transfection of 
Tlr2 mRNA resulted in highly elevated levels of TLR1+ A549 cells compared to 
untransfected controls (Fig. 16C). A slight increase of cells positive for TLR6 
could be detected after transfection of Tlr6 mRNA (Fig. 16D). 
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Fig. 17 TLR expression in MLE12 cells after transfection with Tlr mRNA 
MLE12 cells were transfected with either Tlr1 mRNA or Tlr2 mRNA and subjected to FACS 
analysis 24 hour later. Transfection with Tlr1 mRNA or Tlr2 mRNA led to an increased 
expression of both TLR1 (A) and TLR2 respectively (B) in MLE12 cells. Data are represented as 
means ± SEM. 
Tlr1 and Tlr2 mRNA was furthermore tested in MLE12 cells. Tlr mRNA was 
administered to MLE12 cells via lipofection and incubated for 24 hours. The 
subsequent FACS analysis demonstrated upregulation of both TLR1 (Fig. 17A) 
as well as TLR2 (Fig. 17B) in MLE12 cells after transfection with respective 
mRNA, when compared to untransfected controls. 
3.3 Effects of intratracheal Tlr mRNA delivery on systemic and local 
inflammation in vivo 
3.3.1 Levels of inflammatory cells in BAL 
Mice received combinations of Tlr mRNA at four determined time points before 
sensitization and challenge with HDM. Intratracheal applications were carried 
out under antagonizable anesthesia following the timeline as described in Fig. 
18. At day 15, the predetermined endpoint of the study (32 days after the first 




Fig. 18 Injection schedule for the HDM induced mouse model of asthma 
Mice were treated intratracheally with combinations of Tlr mRNA at day -17, -14, -10 and -7 
prior to the first sensitization with House dust mite extract (HDM), indicated as day 0. Further 
intratracheal injections with HDM followed on day 7 and 14. On day 15, the predetermined 
endpoint of the study, mice were sacrificed and several readouts were performed. (As published 
in [141]) 
Cells of BAL fluid were obtained at the time of sacrifice and differentially 
counted. Levels of inflammatory cells in BAL are presented in Fig. 19. 
 
Fig. 19 Inflammatory cells in BALF 
Intratracheal application of Tlr1/2 mRNA resulted in decreased levels of neutrophils and 
eosinophils in bronchoalveolar lavage fluid (BALF). However treatment with Tlr2/6 mRNA led to 
higher amounts of eosinophils compared to untreated controls but still dampened neutrophilic 
inflammation. Differences between mRNA treated groups and untreated controls were non-
significant with P > 0.05. Data are represented as means ± SEM. (As published in [141]) 
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Fig. 20 Representative micrographs of BALF cellspin preparations 
Lungs were lavaged with PBS and differential cell counts were performed microscopically. 
Scale 100 µm, magnification x200. (As published in [141]) 
Levels of both neutrophils and eosinophils in BAL were decreased after delivery 
of Tlr1/2 mRNA when compared to untreated controls. Application of Tlr2/6 
mRNA led to higher amounts of eosinophils but still dampened neutrophilic 
inflammation. Treatment with Tlr2 mRNA resulted in increased levels of 
neutrophils whereas eosinophils and lymphocytes were slightly reduced. 
However all differences were non-significant (P > 0.05) (Fig. 19). 
Representative micrographs stated in Fig. 20 additionally illustrate the 
distribution of macrophages and inflammatory cells in BALF of differently 
treated groups. 
In order to directly compare the composition of BAL cells of treated and 
untreated mice, Fig. 21 states the data as parts of whole, indicating the 
considerable decline in neutrophils and eosinophils after treatment with Tlr1/2 
mRNA. 




Fig. 21 Cells of BALF presented as parts of whole 
The various BAL cells per group as stated in Fig. 19 are here presented as parts of whole. Data 
are represented as mean percentages. 
3.3.2 Cytokine levels in BAL 
The effect of Tlr mRNA treatment prior to HDM sensitization and challenge was 
further investigated on cytokine levels in BALF supernatant (Fig. 22). BAL fluid 
was collected at the time of sacrifice and centrifuged to obtain the supernatant. 
ELISA technique was used to subsequently determine cytokines in the BAL 
supernatant. 
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Fig. 22 Cytokine levels in BALF analysed using ELISA 
Concentrations of cytokines in bronchoalveolar lavage (BAL) fluid of groups of differently treated 
mice are presented. (A) IFNγ levels were highest after delivery of Tlr1/2 mRNA when compared 
to other mRNA treatments. The dashed line indicates the detection limit of 15 pg/ml. (B) 
Administration of Tlr1/2 and Tlr2/6 mRNA resulted in decreased, administration of Tlr2 mRNA 
however in increased CCL17 concentrations. (C) IL-13 was not detectable in all groups except 
for the HDM control group. IL-5 was not detectable (n.d.) in all samples (data not shown). 
Differences were non-significant. Data are represented as means ± SEM. 
Treatment with Tlr2 and Tlr2/6 mRNA resulted in a moderate decrease of IFNγ 
levels in BALF compared to the HDM control group. Administration of Tlr1/2 
mRNA resulted in the highest IFNγ concentrations compared to other mRNA 
treatments. 
CCL17 levels were markedly reduced after administration of Tlr2/6 and Tlr1/2 
mRNA. Mice treated with Tlr2 mRNA though, showed levels of CCL17 almost 
twice as high as the HDM control group. Concentration of CCL17 in the PBS 
group remained below the assay’s detection limit of 7.8 pg/ml. 
Whereas IL-5 levels were measured but not detectable in all groups, levels of 
IL-13 were decreased after application of Tlr1/2, Tlr2 and Tlr2/6 mRNA when 
compared to mice without Tlr mRNA treatment prior to HDM administration. 
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In order to detect cytokines in BALF more precisely, a bead-based bio-plex 
cytokine assay was performed additionally to the conventional ELISA tests. 
 
Fig. 23 Cytokine levels in BALF analysed using a Bio-Plex cytokine panel 
T cell cytokines in BALF supernatants were quantified using a Th1/Th2 multiplex panel. (A) Th2-
like cytokines were increased after administration of Tlr2 mRNA and slightly decreased after 
treatment with Tlr1/2 mRNA. (B) Levels of Th17-like cytokine IL-17 were elevated after Tlr2 and 
Tlr2/6 mRNA treatment, but not in response to Tlr1/2 mRNA. Administration of Tlr2 mRNA also 
led to increased levels of most Th1-type cytokines (except IFNγ), whereas Tlr1/2 mRNA slightly 
reduced IFNγ concentrations in BALF. Differences remained non-significant. Data are 
represented as means ± SEM. 
Cytokine levels of IL-4, IL-5 and IL-10, mainly secreted by Th2 cells, were 
increased after Tlr2 mRNA treatment and remained unchanged or slightly 
reduced after Tlr1/2 mRNA treatment. Administration of Tlr2/6 mRNA resulted in 
marginally diminished IL-4 levels and barely influenced levels of IL-5 or IL-10 
(Fig. 23 A). 
Concentration of Th17-secreted cytokine IL-17 was increased in response to 
Tlr2 mRNA and Tlr2/6 mRNA treatment and remained unaltered after Tlr1/2 
mRNA treatment (Fig. 23 B). 
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Levels of Th1-type cytokines IL-2, IFNγ and IL-12 were elevated after Tlr2/6 
mRNA treatment. Tlr2 mRNA treatment resulted in higher concentrations of IL-2 
and markedly increased concentrations of TNFα, also mainly secreted by Th1 
cells. Administration of Tlr1/2 mRNA led to diminished levels of IL-2 and IL-12 
and slightly increased concentrations of IFNγ (Fig. 23 B). 
Parts of the results presented in this chapter 3.3.2 have been published in [141]. 
3.3.3 TLR Expression in lung and spleen tissue at the endpoint of the 
study 
The expression of TLR1, 2 and 6 on day 15 (endpoint) was analyzed via Flow 
cytometry to determine whether the administration of Tlr mRNA may have long 
term effects on systemic and/or local TLR expression. Lung and spleen tissue 
was prepared and stained prior to FACS analysis. TLR expression detected in 
lymphocytes, monocytes, PBMCs and neutrophils in spleen tissue of mice 
treated with Tlr mRNA did not differ from TLR expression detected in these cells 
of mice treated with either HDM alone or neither mRNA nor HDM (data not 
shown). TLR expression in cells of lung tissue did also not differ significantly 
from treated to untreated mice. However, an increase in TLR1 and TLR2 
expression on neutrophils was detected after administration of Tlr1/2, Tlr2 as 
well as Tlr2/6 mRNA (Supplement Fig. 1). Furthermore Foxp3+ Tregs were 
analyzed in the same manner and again no differences could be discerned 
between differently treated groups (data not shown). 
3.3.4 Immigration of inflammatory cells into lung and spleen tissue 
In order to investigate both the local effect of Tlr mRNA application on immune 
cells in lung and the systemic effect on spleen tissue, lung and spleen cells 




Fig. 24 Inflammatory cells in lung tissue 
Levels of T cells, neutrophils and eosinophils were measured via flow cytometry. T cell levels in 
the Tlr2 mRNA+HDM group could technically not be detected (#). Differences were non-
significant. Data are represented as means ± SEM. 
Numbers of T cells in lung tissue were reduced after administration of 
Tlr2/6 mRNA. Delivery of Tlr1/2 mRNA was able to dampen eosinophils but 
resulted in increased numbers of T cells. Tlr2 mRNA resulted in augmented 
levels of eosinophils and considerably increased neutrophils in lung tissue (Fig. 
24). 
 
Fig. 25 Inflammatory cells in spleen tissue 
T cells, neutrophils and eosinophils were analyzed using flow cytometry. T cell levels in Tlr2 
mRNA+HDM group could technically not be detected (#). Differences were non-significant. Data 
are represented as means ± SEM. 
3.3 Effects of intratracheal Tlr mRNA delivery on systemic and local 
inflammation in vivo 
69 
In order to further determine a possible systemic effect of Tlr mRNA treatment 
prior to HDM administration, immune cells of spleen tissue were analyzed (Fig. 
25). Here, Tlr2 mRNA led to increased numbers of neutrophils but slightly 
decreased numbers of eosinophils when compared to untreated controls. 
Levels of neutrophils and eosinophils but not T cells in spleen tissue cells were 
increased after delivery of Tlr1/2 mRNA. All differences remained non-
significant. 
Parts of the results presented in this chapter 3.3.4 have been published in [141]. 
3.3.5 Inflammation and mucus production in lung tissue 
At the time of sacrifice, whole lungs were obtained, embedded in paraffin and 
finally cut in sections. Lung tissue sections were then stained with either H&E to 
analyze tissue inflammation or PAS to evaluate mucus production. 
Peribronchial, perivascular and interstitial tissue inflammation in lungs of mice 
treated with Tlr1/2 mRNA was markedly reduced (Fig. 26). Administration of 
Tlr1/2 mRNA resulted in significantly reduced (P = 0.007) numbers of mucus 
producing goblet cells in airways (Fig. 27). Treatment with Tlr2 mRNA led to 
higher degrees of goblet cell metaplasia when compared to untreated controls 
(Fig. 27) and did not dampen lung inflammation. Inflammation of lung tissue 
was slightly diminished after delivery of Tlr2/6 mRNA. No differences in goblet 





Fig. 26 Inflammation and mucus production in lung sections 
Tissue inflammation and goblet cell metaplasia was analyzed on H&E- and PAS-stained lung 
sections. Representative micrographs are shown (scale 100 µm, magnification of H&E sections: 
x200, PAS sections: x400). (As published in [141]) 
3.4 Effects of Tlr mRNA treatment on lung function 
71 
 
Fig. 27 Scoring for mucus producing PAS+ goblet cells 
PAS stained lung sections were analyzed to quantify PAS
+
 goblet cells. Delivery of Tlr2 mRNA 
resulted in increased levels of PAS
+
 cells, whereas delivery of Tlr1/2 mRNA led to significantly 
reduced goblet cell metaplasia (P = 0.007). Data are represented as individual mice, horizontal 
lines state means. (As published in [141]) 
The results presented in this chapter 3.3.5 have been published in [141]. 
3.4 Effects of Tlr mRNA treatment on lung function 
Next, it was investigated whether the delivery of combinations of chemically 
modified Tlr1, 2 and 6 mRNA modulates airway hyperresponsiveness of mice in 
an HDM induced model of asthma. For this purpose, lung function in terms of 
airway resistance was determined by using the model of the isolated, perfused 
and ventilated lung (IPL). 
Here, markedly reduced airway resistance values following methacholine (MCh) 
challenge after administration of Tlr1/2 mRNA prior to HDM challenge were 
observed (Fig. 28). Delivery of Tlr2/6 mRNA was as well associated with 
decreased airway resistance values, hence lower airway hyperresponsiveness. 
However, treatment with Tlr2 mRNA led to increased airway resistance and 
thus a decline in lung function. These mice showed significantly higher 
resistance values than PBS controls and Tlr1/2 mRNA treated mice (Fig. 28). 




Fig. 28 Airway resistance values in response to MCh 
Airway resistance was measured in response to rising concentrations of methacholine (MCh) 
using the isolated, perfused and ventilated lung (IPL). Treatment with Tlr1/2 mRNA resulted in 
reduced airway resistance implying an increase of lung function. Statistical analysis was 
performed separately for each MCh concentration, * and # are PBS vs. the respective group, § 
is Tlr1/2 vs. Tlr2. Data are represented as means, data at 10 µM MCh is additionally stated as 
means ± SEM. (As published in [141]) 
In conclusion, intratracheal administration of combinations of Tlr1/2 and 
Tlr2/6 mRNA resulted in improved lung function whereas intratracheal 
administration of Tlr2 mRNA was associated with reduced lung function when 
compared to negative controls. 
4.1 General remarks 
73 
4 Discussion 
4.1 General remarks 
To elucidate the relationship between TLRs and asthma has been subject of 
ongoing research for some years. Various SNPs have been identified and new 
ligands were discovered. In fact, stimulation of TLRs with specific agonists is 
already subject of clinical studies. Though, TLR gene supplementation in terms 
of mRNA administration hasn’t been investigated so far. This thesis provides 
first insights in the potential of this strategy and suggests Tlr1/2 mRNA 
treatment as asthma-protective [141]. 
In the following sections, the present findings will be discussed in the context of 
previous and current study results, future perspectives and challenges. 
4.2 The importance of mRNA modification and application route 
Chemically modified mRNA has proven to hold great therapeutic potential in 
various fields of applications. Nevertheless, methodological improvements and 
the specific manner of nucleoside modification are still subjects of ongoing 
research. In the present study, mRNA incorporating 25% s2U and 25% m5C 
was used. This modification has proven/shown to yield efficient expression with 
high stability combined with low immunogenicity [127, 130]. In line with these 
findings, at the endpoint of our study, no significant differences in immune 
responses comparing mice treated with mRNA and PBS control groups were 
detected (Supplement Fig. 2). Here, treatment with Tlr2, Tlr1/2 or Tlr2/6 mRNA 
did not promote pulmonary inflammation in terms of increased immigration of 
T cells, neutrophils or eosinophils into lung tissue when compared to PBS 
control mice. However, other modifications, such as 10% s2U and m5C [129], 
pseudouridine-containing mRNA [126, 142, 143] or N(1)-methylpseurdouridine 
(also in combination with m5C) [144] also seem capable of ensuring low 
immunogenicity and high transfection efficiency. Beside biological stability and 
immunological safety, the application manner can be optimized as well. In 
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previous work of our group [127, 129] and also in the present study, mRNA 
(naked, dissolved in nuclease-free water) was delivered intratracheally by using 
a high pressure spraying device. Ambitious efforts to even further improve 
safety and efficacy of an mRNA delivery strategy resulted in introducing 
nanoparticles as vehicles for mRNA. This innovative tool enables various local 
and systemic routes of administration with very interesting results in recent 
publications [130, 145, 146]. Regarding the variety of possibilities, it becomes 
apparent that in terms of mRNA modification and delivery, there may not be one 
universal method or strategy. Rather it will be the challenge of future research 
to adapt chemical modifications and routes of administration precisely to the 
particular target organ or cell type and clinical implementation. 
Continuative studies could also aim to vary the injection schedule of the murine 
asthma model. The injection schedule was designed based on the work of Mays 
et al. (2013) [129] and modified the application time points in order to create a 
preventative approach. Due to its relatively short half-time, mRNA was 
administered not only once but at four time points before the HDM challenge. 
Thereby, it was aimed to create a time frame of temporary TLR-upregulation. 
Interestingly, there is evidence to suggest that this sensitive time frame might 
already take place during pregnancy. In a large cross-sectional study, Ege et al. 
(2006) described that prenatal - thus maternal - exposure to farming 
environments has protective effects against asthma and atopy in children, 
probably via upregulation of innate immune receptors [147]. This observation 
was confirmed by Lundell and colleagues 2015, linking the farm exposure to 
increased levels of the B-cell activating factor. At the level of mouse models, 
maternal exposure to the cowshed-derived bacterium Acinetobacter Iwoffii 
protected the progeny against the onset of asthma through TLR signaling 
mechanisms [148]. The exposure of pregnant mice to combustion derived 
particles, however, interfered with the natural Th1/Th2 cell maturation of the 
offspring’s immune system and resulted in impaired airway 
hyperresponsiveness in the progeny [149]. 
The detailed understanding of prenatal immune processes and their influence 
on the offspring’s immune system remains still to be further investigated. A 
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modification of our injection schedule combined with a pregnant mouse model 
could, for example, enable maternal transient upregulation of certain TLRs. The 
subsequent analysis of both immunophenotype and atopic predisposition of 
their progenies could be an interesting subject of further research in this field. 
4.3 The role of Tlr1, 2 and 6 mRNA application in a mouse asthma model 
4.3.1 Tlr1/2 mRNA application improved asthma phenotype 
In our study, preventative treatment with Tlr1/2 mRNA resulted in decreased 
levels of both eosinophils and neutrophils in BALF. Whereas numbers of 
neutrophils remained constant, eosinophils were also reduced in FACS analysis 
of lung tissue cells. The reduction of these inflammatory cells in treated mice 
indicates a decline of the essential inflammatory component of asthma. 
Concordantly, markedly reduced interstitial and peribronchial tissue 
inflammation in histological lung sections were detected in this group. 
Inflammatory cytokines CCL-17, IL-5 and IL-13, mostly secreted by Th2 cells, 
were slightly reduced after Tlr1/2 mRNA treatment whereas IFNγ as a Th1 
cytokine was increased. However, it might be too early to interpret these results 
as a switch in Th2/Th1 immune response since other Th1 and Th2 cytokines 
remained on the control group’s level after Tlr1/2 mRNA treatment. A general 
problem in our cytokine analysis (regarding Tlr1/2 as well as Tlr2 and Tlr2/6 
mRNA results) could be the overall low concentration of cytokines in all BALF 
samples. For future experiments, less volume of PBS to perform the BALF in 
order to receive higher concentrations of cytokines in each sample could help to 
facilitate cytokine analysis. To overcome this problem, a highly sensitive 
cytokine Multiplex-panel was used additionally to ELISA tests, which allows to 
detect the differences in IL-5 and IFNγ and to run more tests with only small 
sample volumes. 
Besides inflammation, excessive mucus production is another central 
manifestation of asthma. This symptom was significantly decreased after Tlr1/2 
mRNA administration and measured in terms of quantifying peribronchial 
mucus-producing goblet cells. Airway hyperresponsiveness as another key 
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pathophysiological feature of asthma was investigated by means of airway 
resistance following ex vivo methacholine challenge. Here, markedly improved 
results for airway resistance (and hence lung function) were detected for mice 
treated with Tlr1/2 mRNA.  
The role of TLR1/2 positively modulating asthma and lung inflammation has 
also been suggested in some experimental and clinical reports. In a study from 
2008, Koller and colleagues investigated TLR expression on airway neutrophils 
and lung function parameters of patients suffering from cystic fibrosis lung 
disease. Interestingly, improved lung function values correlated positively with 
increased TLR5 expression on airway neutrophils. This TLR5 upregulation 
turned out to be stimulated by bacterial Pam3CSK4 and mediated through 
TLR1/2 signaling [150]. Since TLR5 wasn’t subject of investigation in the 
present study, the further exploration of TLR5 and its’ role as a link between 
TLR1/2 signaling and improved lung function could serve as an interesting 
subject to investigate in an HDM induced mouse model of asthma. More recent 
studies report that stimulation with the TLR1/2 agonist Pam3Cys was found to 
shape immune responses in human peripheral blood leucocytes [151] whereas 
stimulation with the novel lipopeptide LPGerD in a mouse model was able to 
induce an LPS tolerance state in antigen presenting cells, preventing mice from 
allergic sensitization [152]. 
Interestingly, the effect of Tlr1/2 mRNA treatment resulting in improved lung 
function parameters and decreased bronchial inflammation could be repeated in 
a small-scale study performed subsequent to the thesis at hand. This study was 
conducted by Clara Will as her Bachelor thesis in Molecular Medicine at the 
University of Tuebingen. The experimental set-up of this study was designed 
and supervised by Prof. Kormann and me in order to validate the promising 
results of Tlr1/2 mRNA administration obtained from this thesis. For this study, 
mice were treated intratracheally with either Tlr1/2 mRNA or RFP mRNA as a 
mock control (both chemically modified with 25% s2U and 25% m5C). HDM and 
PBS groups served as controls. Mice were exposed to the same injection 
schedule described in Materials and Methods (Fig. 9) though HDM was 
administered intranasally. Concordantly with the findings at hand in this thesis, 
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preventative treatment with Tlr1/2 mRNA again resulted in markedly improved 
lung function values (Supplement Fig. 3). In addition, both neutrophils and 
eosinophils in BAL fluid were significantly reduced after Tlr1/2 mRNA treatment 
when compared to untreated HDM controls (Supplement Fig. 4). 
4.3.2 Ambiguous effect of Tlr2/6 mRNA on asthma outcome 
In our study, treatment with Tlr2/6 mRNA led to decreased levels of neutrophils 
in BALF, reduced pulmonary interstitial inflammation in histological sections and 
lower airway resistance, hence improved lung function. So far, these results 
seem to militate in favor of an asthma protecting effect of Tlr2/6 mRNA 
treatment and in line with previous findings indicating a protective effect of TLR6 
on asthma in humans and in a mouse model [34, 108, 153]. However some 
analysis yielded ambiguous results. In contrast to the results of the present 
study that were mentioned above, some of the findings also pointed rather 
towards enhanced inflammation, such as increased eosinophils in BALF and 
increased neutrophils in FACS analysis of lung tissue. Eosinophil levels in lung 
tissue remained unaltered when compared to untreated controls as were many 
BALF cytokine levels. In Multiplex analysis, IL-17A as a Th17 cytokine was 
distinctly elevated. Regarding the elevated levels of both eosinophils and IL-17A 
in BALF together, it is interesting to mention that eosinophils being elevated in 
sputum and BALF of asthmatic patients have been discussed to represent a 
source of IL-17A (additionally to Th17 cells), driving inflammatory responses 
through the release of proinflammatory mediators [154]. Schnyder-Candrian 
and colleagues reported about IL-17A in a mouse model to play a crucial role in 
both establishing asthma (through inflammatory mediators) but also being able 
to dampen allergic responses, emphasizing its dual role in immune responses 
[155]. When describing the protective role of TLR6 in both a fungal and an HDM 
driven mouse model of asthma, Moreira and colleagues demonstrated this 
effect to be IL-23 and IL17A dependent. In this context, TLR6 activation is 
responsible for Th17 activation through IL-23 and Th17 cells secrete IL17A to 
regulate and restrict allergic inflammatory responses [108]. In HDM and OVA 
induced mouse models of asthma, exogenous administered IL-17A vitiated the 
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protective and therapeutic effect of Foxp3 mRNA treatment on allergic asthma 
[129]. Taken together, these findings indicate that the balanced signaling of 
Th17, Tregs and Th2 cells and their chemokine mediators are of crucial 
importance in allergic asthma immune responses and might explain, in parts, 
the diverse results of the present read-outs after Tlr2/6 mRNA treatment. 
4.3.3 Treatment with Tlr2 mRNA alone worsened asthma symptoms 
Additionally to combinations of heterodimer forming Tlr1/2 and Tlr2/6 mRNA, 
Tlr2 mRNA was administered alone. Remarkably, treatment with Tlr2 mRNA in 
vivo promoted a rather proinflammatory phenotype in our HDM induced mouse 
model of asthma. Percentages of neutrophils, but not eosinophils and 
lymphocytes, were increased in BALF samples at the endpoint of the study. In 
FACS analysis of lung tissue, neutrophils and eosinophils were markedly 
elevated when compared to HDM controls. Inflammation was also intensified in 
pulmonary interstitium and mucus producing goblet cells were augmented, 
analyzed on histological lung sections. Interestingly, also airway resistance of 
Tlr2 mRNA treated mice was markedly increased. These mice had even worse 
lung function values than HDM control mice without mRNA treatment. 
Contradictory results have been reported regarding the association of TLR2 and 
asthma. In view of the hygiene hypothesis stating that farmers’ children are less 
affected by atopic asthma, Lauener and colleagues found increased TLR2 
expression in farmers’ compared to non-farmers’ children. They suggested this 
finding to represent the link between (farming-) environment and decreased risk 
of the onset of allergic asthma [156]. Already previous reports demonstrated a 
therapeutic effect of TLR2 stimulation with lipopeptides such as LP40 [157] or 
Pam3CSK4 [158] in experimental asthma. Liu et al. demonstrated the 
inseparable co-stimulation of TLR2 and TLR4 by HDM, the close cross-talk 
between the two receptor pathways and the resulting Th2-promoting immune 
response [159]. This specific interaction of HDM components and TLR2 mustn’t 
be disregarded in this context though cannot be fully distinguished since TLR4 
was not part of the present study. Finally, in a clinical study following up Finnish 
children, no association between bronchiolitis severity or postbronchiolitis 
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wheezing (frequent pre-stages of childhood asthma) and polymorphisms in 
TLR2 was found [160]. Also an additional follow-up study conducted by this 
group, investigating lung-function in association with TLR polymorphisms, did 
not deliver clearer results in this regard [161]. 
On the contrary and in line with the findings presented in this thesis, there is 
also widespread evidence for TLR2 to be a major contributor in asthma 
pathogenesis. TLR2 has been found to be overexpressed in both patients 
suffering from persistent allergic rhinitis [162] and in fatal asthma patients [112]. 
A mutation in TLR2 was found to relevantly increase not the risk of asthma 
specifically, but the risk of atopy in general in a German population [113]. 
Another polymorphism in TLR2 was significantly associated with asthma and 
also diabetes type 1 (an immune-mediated type of diabetes characterized by 
destruction of insulin-producing beta cells) in a large cohort of Norwegian 
children [117]. In a mouse model using ovalbumin instead of HDM to induce 
asthma, allergic responses in terms of AHR, airway inflammation, Th2 cytokine 
levels and mucus cell metaplasia were significantly reduced in TLR2 knockouts 
compared to TLR2 wildtype mice. The authors reasoned, TLR2 might function 
as a crucial mediator of the Th2-cytokine-driven inflammatory component of 
asthma [163]. The importance of the interrelation between TLR2 activation and 
a Th2 biased immune response was already proposed by Redecke et al., who 
observed how TLR2 activation aggravated experimental asthma [164]. 
When viewed in combination, the results of these reports suggest a complex 
role of TLR2 in the development of allergic asthma. Some of these controversial 
results might arise, in part, from imprecise differentiation into whether results 
are consequences of TLR2 protein expression levels, gene polymorphisms or 
heterodimerization with either TLR1 or TLR6. Particular single nucleotide 
polymorphism, specific TLR ligands, gene-gene interactions and the 
combination of these factors probably collude to orchestrate Th immune 




4.4 Future prospects 
Recapitulating the immunological mechanisms that are contributing to atopy 
and allergy, it seems tempting to simply manipulate TLR pattern and Th1/Th2 
balance in order to interfere with the pathogenesis of asthma. Treatment with 
tailored TLR mRNA transcripts could represent such a conceivable therapeutic 
approach and has been introduced in an animal model in the present study. 
However, one of the main difficulties remains the dual role of TLRs. Depending 
on the disease, both excessive TLR signaling or insufficient TLR function can 
lead to pathological conditions. Hence, treating one condition might lead to the 
next, undesirable immune-mediated illness. Both TLR agonists (e.g. a TLR9 
agonist [165, 166]) and antagonists (e.g. for TLR2 or 4, reviewed in [167]) for 
various applications are currently evaluated in clinical trials. However, TLR1/2 
or TLR2/6 agonists are to date not yet part of these clinical studies. 
Systemically influenced TLR pattern may change TLR homeostasis entirely 
different in various organ systems (such as airways, urinary or gastrointestinal 
tract), thus therapeutic manipulation should be carefully considered. 
Downstream signaling mechanisms in terms of influencing Th1/Th2 responses 
can appear as a logical target for treating auto-inflammatory (mostly caused by 
exaggerated Th1 response) or atopic (driven by Th2 biased immune responses) 
diseases. Precise dosing and timing would be essential to ensure that treatment 
of one condition doesn’t result in the other. 
Even though much has been learned about TLRs and their respective ligands, 
their interaction is still complex. Cross-reactions of TLR signaling should be 
taken into consideration and also the fact that agonists might act differently in 
natural occurring combinations and doses than purified ligands as tested under 
sterile conditions. Furthermore, the actual ligand dose is also likely to influence 
signaling, as shown for LPS-stimulation of TLR4 [168]. It becomes evident that 
deep and thorough understanding of the role of TLRs is a crucial precondition 
when composing TLR-based therapies. 
The progress accomplished in the last years in designing highly effective 
chemically modified mRNA transcripts might represent the ideal tool for such 
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TLR-targeting therapies. Current efforts to introduce nanoparticles as vehicles 
for guiding mRNA to cellular destinations even increased the efficacy [130, 
146]. Further studies should now optimize custom-designed chemical mRNA 
modifications and application routes. Overall, this novel method might be 
available for broader fields of application in the future. 
However, the present data should be assessed considering some limitations 
this study comprises. The experimental design implies a rather small number of 
mice and matches the character of a pilot-study with implications for 
subsequent large-scale studies. Preliminary work [34] emphasizes the role of 
TLR SNPs in human asthma and their manifold impact on downstream 
signaling and onset of the disease. In the present study, conventional Balb/C 
mice and not humanized mice were used, with the consensus coding sequence 
(CCDS) murine Tlr genes as stated in the CCDS database at 
www.ncbi.nlm.nih.gov. 
Despite various challenges, the need for new, innovative treatment options is 
obvious: Asthma is a major burden worldwide and available asthma 
medications are often accompanied by disturbing side effects. Current 
treatment approaches affect asthma symptoms but are unable to prevent the 
development of the disease. They furthermore do not account for patient 
specific immune backgrounds and are sometimes not even approved for 
application in children. Especially cases of severe asthma are still hard to 
control and can be life threatening [169-171]. Controlled, site-specific 
modulation of TLR expression via chemically modified mRNA might represent 
such a therapeutic tool. This novel approach may furthermore have preventative 
potential. The concept introduced in this thesis might serve as a starting point 
for further large-scale studies to both validate the present results and broaden 
the analysis to gain more detailed information. The concept of this study could 
also be applicable to other atopic and immune-mediated diseases with 





Asthma is the most common chronic disease in childhood. Environmental 
factors and genetic predisposition are key factors influencing the pathogenesis 
of the disease, operating in constant interaction. 
Considering the environmental factors, exposure to an environment rich in 
microbes in early life (and already during pregnancy [148]) reduces the risk of 
atopic asthma [13, 55, 172]. Beside environmental aspects, the atopic genetic 
predisposition to produce IgE-antibodies in response to environmental allergens 
[7], plays a crucial role in the pathogenesis and facilitates the onset of the 
disease. At the interface between genes and environment, Toll-like receptors 
(TLRs) are viewed as gate-keepers of the immune system. They are capable of 
recognizing microbial components and influence immune responses as well as 
gene expression via intracellular signaling. 
Studies investigating the role of TLRs in asthma pathogenesis suggest a 
protective role of TLR6 activation in mice [108]. Heterodimer variants of TLR1, 6 
and 10 (all capable of forming heterodimers with TLR2) and increased protein 
expression of these TLRs were found to have protective effects on childhood 
asthma [34]. 
The therapeutic administration of chemically modified mRNA represents a 
promising tool to interfere with these genetic processes therapeutically. Not only 
as a treatment strategy for severe lung diseases [129, 130] but also in other 
fields of application [143, 145] the therapeutical potential of mRNA has been 
demonstrated. In contrast to approaches in gene therapy utilizing AAV vectors, 
chemically modified mRNA circumvents the threat of genomic integration and 
yields high transfer efficiency combined with low immunogenicity. 
Based upon these findings, the present study was designed to test the effect of 
a preventative treatment with combinations of Tlr1, Tlr2 and Tlr6 mRNA in a 
HDM driven mouse model of asthma. Murine Tlrs were cloned into a plasmid 
vector in order to subsequently produce in vitro transcribed chemically modified 
Tlr1, Tlr2 and Tlr6 mRNA. Balb/c mice received mRNA and HDM extract 
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intratracheally. FACS analysis of lung and spleen cells, differential cell count of 
BALF and histology of whole lung sections were performed. Additionally, BALF 
cytokines were detected and lung function as well as airway resistance via IPL 
was measured. 
After treatment with Tlr1/2 mRNA decreased portions of both neutrophils and 
eosinophils in BALF were detected. In addition, eosinophils were also 
diminished in lung tissue cells. Furthermore considerably reduced tissue 
inflammation and significantly decreased mucus producing goblet cells were 
observed in this group. Application of Tlr1/2 mRNA resulted in markedly 
reduced airway resistance and hence improved lung function compared to 
untreated HDM controls. Mice treated with Tlr2 mRNA presented aggravated 
asthma symptoms with an elevated numbers of neutrophils in BALF and lung 
cells. Further symptoms were increased tissue inflammation and mucus 
production in lung histology as well as declined lung function. Administration of 
Tlr2/6 mRNA led to reduced portions of neutrophils in BALF yet elevated levels 
of these cells in lung tissue. Analysis of lung histology yielded a slight reduction 
of tissue inflammation but no decline of mucus production whereas lung 
function values were considerably improved in this group.  
Summing up, a protective effect of the treatment with chemically modified 
Tlr1/2 mRNA in an HDM induced mouse model of asthma was observed. 
Although application of Tlr2/6 mRNA was also able to improve lung function, 
further studies will be necessary to prove a clear effect. Administration of Tlr2 
mRNA however, resulted in an aggravated asthma phenotype. 
The concept of this study combines new insights into the role of TLRs in atopic 
asthma with novel therapeutic tools such as chemically modified mRNA 
transcripts. Early treatment with tailored mRNA transcripts could provide a new 
therapeutic and even preventative approach in asthma management. 
Modification of TLR expression via chemically modified mRNA might 
furthermore have protective effects on other atopic and inflammatory diseases, 




Asthma ist die häufigste chronische Erkrankung im Kindesalter. Umweltfaktoren 
und genetische Veranlagung beeinflussen entscheidend die Entstehung der 
Erkrankung und stehen in enger Wechselwirkung. 
Bezüglich der Umweltfaktoren verringert sich das Risiko, an atopischem 
Asthma zu erkranken, wenn der Organismus in früher Kindheit (oder schon 
während der Schwangerschaft [148]) einer Umgebung mit hoher mikrobieller 
Belastung ausgesetzt ist [13, 55, 172]. Neben Umweltfaktoren spielt die 
genetisch bedingte atopische Prädisposition eine entscheidende Rolle - eine 
überschießende IgE-Antikörperproduktion als Antwort auf Umweltallergene 
begünstigt hier die Entstehung der Erkrankung [7]. An der Schnittstelle 
zwischen Umwelt und Genetik fungieren Toll-like Rezeptoren (TLRs) als 
sogenannte „Torhüter“ des Immunsystems. Sie können mikrobielle Bestandteile 
aus der Umwelt erkennen und über intrazelluläre Signalwege sowohl die 
Immunantwort als auch die Genexpression modulieren. Studien zur Rolle der 
TLRs in der Asthma-Pathogenese deuten auf eine schützende Wirkung einer 
TLR6-Aktivierung im Mausmodell hin [108]. Heterodimer Varianten in TLR1, 6 
und 10 sowie erhöhte Expression dieser TLRs erwiesen sich als protektiver 
Faktor bezüglich Asthma im Kindesalter [34]. 
Chemisch modifizierte mRNA bietet einen vielversprechenden Ansatz, in diese 
genetischen Abläufe therapeutisch einzugreifen. Nicht nur in der Behandlung 
schwerer Lungenerkrankungen [129, 130] sondern auch in anderen 
Anwendungsgebieten [143, 145] wurde das therapeutische Potenzial mRNA 
basierter Therapie bereits demonstriert. Im Gegensatz zum Ansatz einer 
Gentherapie mit AAV-Vektoren, umgeht chemisch modifizierte mRNA die 
Gefahr der genomischen Integration bei gleichzeitig niedriger Immunogenität. 
Basierend auf diesen Erkenntnissen wurde die vorliegende Studie entwickelt, 
mit dem Ziel, den Effekt einer präventiven Behandlung mit Kombinationen von 
Tlr1, Tlr2 und Tlr6 mRNA in einem durch HDM induzierten Asthma-Mausmodell 
zu erforschen. Murine Tlrs wurden in einen Plasmidvektor geklont, um 
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anschließend in vitro transkribierte chemisch modifizierte Tlr1, Tlr2, und Tlr6 
mRNA herzustellen. Balb/c Mäuse erhielten mRNA und HDM Extrakt 
intratracheal. FACS Analysen von Lungen- und Milz-Zellen, sowie eine 
differentielle Zellzählung der BALF wurden durchgeführt. Außerdem wurden die 
Histologie von Lungenabschnitten untersucht, BALF-Zytokine detektiert und die 
Lungenfunktion und Atemwegswiderstände mittels IPL gemessen. 
Nach der Behandlung mit Tlr1/2 mRNA zeigte sich ein Rückgang sowohl von 
Neutrophilen als auch Eosinophilen in der BALF. Auch in den 
Lungengewebszellen ging die Zahl der Eosinophilen zurück. Zusätzlich konnte 
in dieser Gruppe in der Lungenhistologie ein deutlicher Rückgang der 
Gewebsentzündung sowie eine signifikant reduzierte Zahl Mukus-
produzierender Becherzellen festgestellt werden. In der IPL zeigten sich 
erheblich reduzierte Atemwegswiderstände der Tlr1/2 mRNA Gruppe, also eine 
verbesserte Lungenfunktion im Vergleich zu unbehandelten HDM Kontrolltieren. 
Die Behandlung mit Tlr2 mRNA führte zu verschlechterten Asthmasymptomen 
mit einem Anstieg der Neutrophilen in BALF und Lungengewebe, gesteigerter 
Gewebsentzündung und Mukusproduktion sowie höheren 
Atemwegswiderständen als in der Asthmakontrollgruppe. Die Gabe von Tlr2/6 
mRNA führte zwar in der BALF zu erniedrigten Anteilen an Neutrophilen, 
welche jedoch im Lungengewebe erhöht waren. Die Analyse der 
Lungenhistologie zeigte einen leichten Rückgang der Gewebsentzündung mit 
etwa unveränderter Mukusproduktion. Die Lungenfunktion dieser Gruppe 
lieferte wiederum deutlich verbesserte Werte im Vergleich zur HDM 
Kontrollgruppe.  
Zusammenfassend zeigte sich in dieser Studie ein protektiver Effekt der 
Behandlung mit chemisch modifizierter Tlr1/2 mRNA auf Asthma in einem 
HDM-induzierten Mausmodell. Eine Behandlung mit Tlr2/6 mRNA verbesserte 
zwar ebenfalls die Lungenfunktion, weiterführende Studien sind hier allerdings 
notwendig um einen eindeutigen Effekt nachzuweisen. Die Gabe von Tlr2 
mRNA hingegen hatte einen aggravierten Asthmaphänotyp zur Folge. 
6 Zusammenfassung 
86 
Die vorliegende Studie liefert neue Einblicke in die Rolle von TLRs in 
atopischem Asthma kombiniert mit neuen therapeutischen Möglichkeiten, wie 
chemisch modifizierter mRNA. Eine frühe Therapie mit maßgeschneiderten 
mRNA Transkripten könnte einen neuen therapeutischen oder sogar 
präventiven Behandlungsansatz im Asthmamanagement liefern. Die 
Modifikation der TLR-Expression mittels modifizierter mRNA könnte 
desweiteren schützende Effekte auf weitere Erkrankungen des atopischen 
Formenkreises bieten und stellt folglich einen vielversprechenden Ansatzpunkt 
für weiterführende Studien dar. 
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Supplement Fig. 1 TLR expression in lung tissue cells at the end of the study 
Cells of lung tissue were harvested at the predetermined endpoint of the study, stained and 
subjected to flow cytometry analysis. Expression of TLR1, 2 and 6 were detected on 




Supplement Fig. 2 Treatment with Tlr mRNA alone does not lead to increased 
lung inflammation 
Mice were treated intratracheally with Tlr1, 2 and 6 mRNA according to the injection schedule. 
A) Cytokines in BAL were measured by ELISA, the dashed line indicates the detection limit of 
15 pg/ml. IL-5 was measured but not detectable in all samples. n.d. = not detectable. B) Cell 
infiltration of T cells, neutrophils and eosinophils in lung tissue was analyzed via flow cytometry. 
* = no valid detection due to technical antibody issue. All data are stated as means ± SEM, n=3. 
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Supplement Fig. 3 Airway resistance values in response to MCh, Bachelor 
thesis C. Will 
Airway resistance was measured in response to rising concentrations of methacholine (MCh) 
using the isolated, perfused and ventilated lung (IPL). Mice were treated with either Tlr1/2 
mRNA or mock RFP mRNA prior to HDM sensitization and challenge. Control groups received 
HDM without preventative mRNA treatment or only PBS. Differences were non-significant. Data 




Supplement Fig. 4 Inflammatory cells in BAL, Bachelor thesis C. Will 
Differential cell count of bronchoalveolar lavage indicating percentages of inflammatory cells. 
Mice were treated with either Tlr1/2 mRNA or mock RFP mRNA prior to HDM sensitization and 
challenge. Control groups received HDM without preventative mRNA treatment or only PBS. 
Intratracheal application of Tlr1/2 mRNA led to significantly decreased levels of both neutrophils 
and eosinophils in BAL fluid (P < 0.05). Data are represented as means ± SEM. [Clara Will, 
Bachelor Thesis, Universität Tübingen, 2015] 
. 
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